Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ovarian Neoplasms

  Free Subscription

Articles published in
Gynecol Oncol
    September 2021
  1. GAILLARD S, Oaknin A, Ray-Coquard I, Vergote I, et al
    Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
    Gynecol Oncol. 2021 Sep 11. pii: S0090-8258(21)01330.
    >> Share

  2. MOSS HA, Chen L, Hershman DL, Davidson B, et al
    Adherence to PARP inhibitor therapy among women with ovarian cancer.
    Gynecol Oncol. 2021 Sep 9. pii: S0090-8258(21)01323.
    >> Share

  3. WERNER B, Yuwono N, Duggan J, Liu D, et al
    Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer.
    Gynecol Oncol. 2021;162:720-727.
    >> Share

  4. CAMPBELL R, King MT, Ross TL, Cohen PA, et al
    Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment.
    Gynecol Oncol. 2021 Sep 1. pii: S0090-8258(21)01320.
    >> Share

    August 2021
  5. FUH KC, Bookman MA, Liu JF, Coleman RL, et al
    Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
    Gynecol Oncol. 2021 Aug 30. pii: S0090-8258(21)01318.
    >> Share

  6. STEENBEEK MP, van Bommel MHD, Harmsen MG, Hoogerbrugge N, et al
    Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy.
    Gynecol Oncol. 2021 Aug 26. pii: S0090-8258(21)01317.
    >> Share

  7. POZZAR RA, Xiong N, Hong F, Wright AA, et al
    Perceived patient-centered communication, quality of life, and symptom burden in individuals with ovarian cancer.
    Gynecol Oncol. 2021 Aug 25. pii: S0090-8258(21)00652.
    >> Share

  8. LUTGENDORF SK, Ramirez E, Schrepf A, Valentine MC, et al
    Rural residence is related to shorter survival in epithelial ovarian cancer patients.
    Gynecol Oncol. 2021 Aug 13. pii: S0090-8258(21)00601.
    >> Share

  9. WETHINGTON SL, Wahner-Hendrickson AE, Swisher EM, Kaufmann SH, et al
    PARP inhibitor maintenance for primary ovarian cancer - A missed opportunity for precision medicine.
    Gynecol Oncol. 2021 Aug 11. pii: S0090-8258(21)00647.
    >> Share

  10. WENTZENSEN N, O'Brien KM
    Talc, body powder, and ovarian cancer: A summary of the epidemiologic evidence.
    Gynecol Oncol. 2021 Aug 5. pii: S0090-8258(21)00598.
    >> Share

  11. COLOMBO N, Moore K, Scambia G, Oaknin A, et al
    Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.
    Gynecol Oncol. 2021 Aug 2. pii: S0090-8258(21)00578.
    >> Share

    July 2021
  12. BANTIE L, Tadesse S, Likisa J, Yu M, et al
    Erratum to "A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer" [Gynecologic Oncology 159 (2020) 827-838].
    Gynecol Oncol. 2021 Jul 30. pii: S0090-8258(21)00580.
    >> Share

  13. VILLANUEVA C, Chang J, Ziogas A, Bristow RE, et al
    Ambient air pollution and ovarian cancer survival in California.
    Gynecol Oncol. 2021 Jul 27. pii: S0090-8258(21)00602.
    >> Share

  14. NANEZ A, Stram DA, Garcia C, Powell CB, et al
    Ovarian cancer surveillance in the clinical follow up of women with known BRCA1 or BRCA2 pathogenic variants in a large health care system.
    Gynecol Oncol. 2021 Jul 27. pii: S0090-8258(21)00600.
    >> Share

  15. LAZURKO C, Clark M, Pulman K, Lennox G, et al
    Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.
    Gynecol Oncol. 2021 Jul 26. pii: S0090-8258(21)00589.
    >> Share

  16. BASARAN D, Boerner T, Suhner J, Sassine D, et al
    Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy.
    Gynecol Oncol. 2021 Jul 23. pii: S0090-8258(21)00592.
    >> Share

  17. EOH KJ, Park EY, Chang YJ, Ha HI, et al
    The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Jul 22. pii: S0090-8258(21)00590.
    >> Share

  18. MOSS HA, Perhanidis JA, Havrilesky LJ, Secord AA, et al
    Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2021 Jul 20. pii: S0090-8258(21)00588.
    >> Share

  19. CIBULA D, Rob L, Mallmann P, Knapp P, et al
    Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
    Gynecol Oncol. 2021 Jul 19. pii: S0090-8258(21)00533.
    >> Share

  20. ZENG H, Chen L, Zhang M, Luo Y, et al
    Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer.
    Gynecol Oncol. 2021 Jul 15. pii: S0090-8258(21)00577.
    >> Share

  21. RASMUSSEN M, Lim K, Rambech E, Andersen MH, et al
    Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
    Gynecol Oncol. 2021 Jul 15. pii: S0090-8258(21)00531.
    >> Share

  22. KURODA Y, Chiyoda T, Kawaida M, Nakamura K, et al
    ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.
    Gynecol Oncol. 2021 Jul 13. pii: S0090-8258(21)00536.
    >> Share

  23. HERMENS M, van Altena AM, Bulten J, van Vliet HAAM, et al
    Increased incidence of ovarian cancer in both endometriosis and adenomyosis.
    Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00535.
    >> Share

  24. HUFFMAN DL, Jayakrishnan TT, Shankar K, Peterson CE, et al
    Disparities in ovarian cancer treatment and overall survival according to race: An update.
    Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00541.
    >> Share

  25. VAN DER PLOEG P, Uittenboogaard A, Thijs AMJ, Westgeest HM, et al
    The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2021 Jul 10. pii: S0090-8258(21)00538.
    >> Share

  26. GRUNER M, Chambers LM, Yao M, Chichura A, et al
    Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.
    Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00530.
    >> Share

  27. KRASNER CN, Campos SM, Young CL, Chadda KR, et al
    Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
    Gynecol Oncol. 2021 Jul 6. pii: S0090-8258(21)00532.
    >> Share

    June 2021
  28. BENOIT L DR, Zerbib J Dr, Koual M Dr, Nguyen-Xuan HT Dr, et al
    What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery?
    Gynecol Oncol. 2021 Jun 30. pii: S0090-8258(21)00521.
    >> Share

  29. SAFRA T, Waissengrin B, Gerber D, Bernstein-Molho R, et al
    Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.
    Gynecol Oncol. 2021 Jun 22. pii: S0090-8258(21)00489.
    >> Share

  30. BALDEWPERSAD TEWARIE NMS, van Driel WJ, van Ham M, Wouters MW, et al
    Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA).
    Gynecol Oncol. 2021 Jun 16. pii: S0090-8258(21)00436.
    >> Share

  31. JIANG C, Li Z
    Performance validation of the Mayo triage algorithm applied to individualize surgical management of advanced epithelial ovarian cancer.
    Gynecol Oncol. 2021 Jun 16. pii: S0090-8258(21)00483.
    >> Share

  32. VAN DER ZANDEN V, van Soolingen NJ, Viddeleer AR, Trum JW, et al
    Low preoperative skeletal muscle density is predictive for negative postoperative outcomes in older women with ovarian cancer.
    Gynecol Oncol. 2021 Jun 7. pii: S0090-8258(21)00445.
    >> Share

  33. AGHAJANIAN C, Bookman MA, Fleming GF, Swisher EM, et al
    Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
    Gynecol Oncol. 2021 Jun 7. pii: S0090-8258(21)00437.
    >> Share

  34. CASPER AC, Parsons MW, Chipman J, Burt LM Jr, et al
    Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00440.
    >> Share

  35. LI S, Bercow AS, Falzone M, Kalyanaraman R, et al
    Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00438.
    >> Share

  36. HANLEY GE, Kaur P, Berchuck A, Chase A, et al
    Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00427.
    >> Share

  37. ALVAREZ SECORD A, O'Malley DM, Sood AK, Westin SN, et al
    Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
    Gynecol Oncol. 2021 Jun 2. pii: S0090-8258(21)00424.
    >> Share

  38. SHARMA A, Singh M, Chauhan R, Malik PS, et al
    Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
    Gynecol Oncol. 2021 Jun 1. pii: S0090-8258(21)00431.
    >> Share

    May 2021
  39. FRANGOU E, Bertelli G, Love S, Mackean MJ, et al
    OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer.
    Gynecol Oncol. 2021 May 28. pii: S0090-8258(21)00430.
    >> Share

  40. HAVRILESKY LJ, Scott AL, Davidson BA, Secord AA, et al
    The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.
    Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00428.
    >> Share

  41. DE JONG JM, Hoogendam JP, Braat AJAT, Zweemer RP, et al
    The feasibility of folate receptor alpha- and HER2-targeted intraoperative fluorescence-guided cytoreductive surgery in women with epithelial ovarian cancer: A systematic review.
    Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00423.
    >> Share

  42. LIN J, Sharaf RN, Saganty R, Ahsan D, et al
    Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.
    Gynecol Oncol. 2021 May 19. pii: S0090-8258(21)00407.
    >> Share

  43. HEMMINGSEN CH, Kjaer SK, Bennetsen AKK, Dehlendorff C, et al
    The association of reproductive factors with risk of non-epithelial ovarian cancer and comparison with serous ovarian cancer.
    Gynecol Oncol. 2021 May 17. pii: S0090-8258(21)00404.
    >> Share

  44. KIM SI, Yoon S, Kim TM, Cho JY, et al
    Prognostic implications of body composition change during primary treatment in patients with ovarian cancer: A retrospective study using an artificial intelligence-based volumetric technique.
    Gynecol Oncol. 2021 May 13. pii: S0090-8258(21)00363.
    >> Share

  45. CHAM S, Huang Y, Melamed A, Worley MJ Jr, et al
    Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival.
    Gynecol Oncol. 2021 May 5. pii: S0090-8258(21)00352.
    >> Share

  46. GAMBLE CR, Huang Y, Wright JD, Hou JY, et al
    Precision medicine testing in ovarian cancer: The growing inequity between patients with commercial vs medicaid insurance.
    Gynecol Oncol. 2021 May 3. pii: S0090-8258(21)00345.
    >> Share

    April 2021
  47. MULLINS MA, Ruterbusch JJ, Clarke P, Uppal S, et al
    Continuity of care and receipt of aggressive end of life care among women dying of ovarian cancer.
    Gynecol Oncol. 2021 Apr 27. pii: S0090-8258(21)00344.
    >> Share

  48. GIANNONE G, Scotto G, Katsaros D, De Giorgi U, et al
    Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.
    Gynecol Oncol. 2021 Apr 22. pii: S0090-8258(21)00328.
    >> Share

  49. THUSGAARD CF, Korsholm M, Koldby KM, Kruse TA, et al
    Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review.
    Gynecol Oncol. 2021 Apr 20. pii: S0090-8258(21)00330.
    >> Share

  50. SWAYZE EJ, Strzyzewski L, Avula P, Zebolsky AL, et al
    The impact of expanding gynecologic oncology care to ovarian cancer patients in small cities and rural communities.
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00331.
    >> Share

  51. MARTINEZ A, Buckley M, Scalise CB, Katre AA, et al
    Understanding the effect of mechanical forces on ovarian cancer progression.
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00273.
    >> Share

  52. ARTIOLI G, Giannone G, Valabrega G, Maggiorotto F, et al
    Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00324.
    >> Share

  53. DENG M, Wu D, Zhang Y, Jin Z, et al
    MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer.
    Gynecol Oncol. 2021 Apr 17. pii: S0090-8258(21)00323.
    >> Share

  54. NITECKI R, Fleming ND, Fellman BM, Meyer LA, et al
    Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00322.
    >> Share

  55. GUPTA VG, Hirst J, Petersen S, Roby KF, et al
    Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00325.
    >> Share

  56. TONE AA, McCuaig JM, Ricker N, Boghosian T, et al
    The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches.
    Gynecol Oncol. 2021 Apr 13. pii: S0090-8258(21)00321.
    >> Share

  57. FLEMING ND, Westin SN, Rauh-Hain JA, Soliman PT, et al
    Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.
    Gynecol Oncol. 2021 Apr 7. pii: S0090-8258(21)00272.
    >> Share

  58. CHASE DM, Neighbors J, Perhanidis J, Monk BJ, et al
    Gastrointestinal symptoms and diagnosis preceding ovarian cancer diagnosis: Effects on treatment allocation and potential diagnostic delay.
    Gynecol Oncol. 2021 Apr 1. pii: S0090-8258(21)00259.
    >> Share

    March 2021
  59. MALLEN A, Todd S, Robertson SE, Kim J, et al
    Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer.
    Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00228.
    >> Share

  60. GIL-MORENO A, Alonso-Alconada L, Diaz-Feijoo B, Domingo S, et al
    M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients.
    Gynecol Oncol. 2021 Mar 29. pii: S0090-8258(21)00260.
    >> Share

  61. CARTMEL B, Hughes M, Ercolano EA, Gottlieb L, et al
    Randomized trial of exercise on depressive symptomatology and brain derived neurotrophic factor (BDNF) in ovarian cancer survivors: The Women's Activity and Lifestyle Study in Connecticut (WALC).
    Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00195.
    >> Share

  62. FILIPPOVA OT, Tin AL, Alonso J, Vickers AJ, et al
    Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer.
    Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00252.
    >> Share

  63. LOREEN A, Polen-De C, Monk BJ, Jackson AL, et al
    The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00176.
    >> Share

  64. HASSELGREN E, Hertzberg D, Camderman T, Bjorne H, et al
    Perioperative fluid balance and major postoperative complications in surgery for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00179.
    >> Share

  65. ROCCONI RP, Monk BJ, Walter A, Herzog TJ, et al
    Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
    Gynecol Oncol. 2021 Mar 11. pii: S0090-8258(21)00229.
    >> Share

  66. MORDEN CR, Farrell AC, Sliwowski M, Lichtensztejn Z, et al
    Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
    Gynecol Oncol. 2021 Mar 10. pii: S0090-8258(21)00199.
    >> Share

  67. LAGO V, Montero B, Lopez S, Padilla-Iserte P, et al
    Ultrastaging protocol in sentinel lymph node for apparent early stage ovarian cancer.
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00193.
    >> Share

  68. BUECHEL ME, Enserro D, Burger RA, Brady MF, et al
    Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00177.
    >> Share

  69. HUANG C, Lin X, He J, Liu N, et al
    Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2021 Mar 2. pii: S0090-8258(21)00169.
    >> Share

  70. AUBREY C, Saad N, Kobel M, Mattatall F, et al
    Implications for management of ovarian cancer in a transgender man: Impact of androgens and androgen receptor status.
    Gynecol Oncol. 2021 Mar 1. pii: S0090-8258(21)00158.
    >> Share

    February 2021
  71. SCHRIER E, Xiong N, Thompson E, Poort H, et al
    Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors.
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00168.
    >> Share

  72. SJOQUIST KM, Espinoza D, Mileshkin L, Ananda S, et al
    REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00109.
    >> Share

  73. AREND RC, Monk BJ, Herzog TJ, Moore KN, et al
    Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum r
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00151.
    >> Share

  74. KURTZ JE, Gebski V, Sukhin V, Carey M, et al
    Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
    Gynecol Oncol. 2021 Feb 18. pii: S0090-8258(21)00155.
    >> Share

  75. INCI MG, Anders L, Woopen H, Richter R, et al
    Frailty Index for prediction of surgical outcome in ovarian cancer: Results of a prospective study.
    Gynecol Oncol. 2021 Feb 16. pii: S0090-8258(21)00149.
    >> Share

  76. BAANDRUP L, Dehlendorff C, Hertzum-Larsen R, Hannibal CG, et al
    Prognostic impact of socioeconomic status on long-term survival of non-localized epithelial ovarian cancer The Extreme study.
    Gynecol Oncol. 2021 Feb 11. pii: S0090-8258(21)00102.
    >> Share

  77. DAHM-KAHLER P, Holmberg E, Holtenman M, Radestad AF, et al
    Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.
    Gynecol Oncol. 2021 Feb 10. pii: S0090-8258(21)00059.
    >> Share

  78. CHAMBERS LM, Yao M, Morton M, Gruner M, et al
    Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00099.
    >> Share

  79. LIU S, Kasherman L, Fazelzad R, Wang L, et al
    The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Feb 2. pii: S0090-8258(21)00088.
    >> Share

    January 2021
  80. HARRISON RF, Cantor SB, Sun CC, Villanueva M, et al
    Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.
    Gynecol Oncol. 2021 Jan 31. pii: S0090-8258(21)00084.
    >> Share

  81. PIZZOFERRATO AC, Klein M, Fauvet R, Durand C, et al
    Pelvic floor disorders and sexuality in women with ovarian cancer: A systematic review.
    Gynecol Oncol. 2021 Jan 27. pii: S0090-8258(21)00086.
    >> Share

  82. TOZZI R, Traill Z, Valenti G, Ferrari F, et al
    A prospective study on the diagnostic pathway of patients with stage IIIC-IV ovarian cancer: Exploratory laparoscopy (EXL) + CT scan VS. CT scan.
    Gynecol Oncol. 2021 Jan 26. pii: S0090-8258(21)00060.
    >> Share

  83. CASTLE PE, Locke A, Tergas AI, Befano B, et al
    The relationship of human papillomavirus and cytology co-testing results with endometrial and ovarian cancer diagnoses.
    Gynecol Oncol. 2021 Jan 13. pii: S0090-8258(21)00052.
    >> Share

  84. SCHEEPERS ERM, de Rooij BH, Pijnenborg JMA, van Huis-Tanja LH, et al
    Perceived social support in patients with endometrial or ovarian cancer: A secondary analysis from the ROGY care study.
    Gynecol Oncol. 2021 Jan 13. pii: S0090-8258(20)34246.
    >> Share

  85. BILBAO M, Aikins JK, Ostrovsky O
    Is routine omentectomy of grossly normal omentum helpful in surgery for ovarian cancer? A look at the tumor microenvironment and its clinical implications.
    Gynecol Oncol. 2021 Jan 9. pii: S0090-8258(20)34248.
    >> Share

  86. HAGEMANN IS, Deng W, Zaino RJ, Powell MA, et al
    The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.
    Gynecol Oncol. 2021 Jan 7. pii: S0090-8258(20)34255.
    >> Share

  87. DELLINGER TH, Han ES
    State of the Science: The role of HIPEC in the treatment of ovarian cancer.
    Gynecol Oncol. 2021 Jan 5. pii: S0090-8258(20)34243.
    >> Share

  88. HEUS C, Smorenburg A, Stoker J, Rutten MJ, et al
    Visceral obesity and muscle mass determined by CT scan and surgical outcome in patients with advanced ovarian cancer. A retrospective cohort study.
    Gynecol Oncol. 2021;160:187-192.
    >> Share

  89. FADADU PP, Polen-De CL, McGree ME, Weaver AL, et al
    Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation.
    Gynecol Oncol. 2021;160:40-44.
    >> Share

    December 2020
  90. DUSKA LR, Krasner CN, O'Malley DM, Hays JL, et al
    A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Gynecol Oncol. 2020 Dec 31. pii: S0090-8258(20)34228.
    >> Share

  91. BOERNER T, Walch HS, Nguyen B, Iasonos A, et al
    Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study.
    Gynecol Oncol. 2020 Dec 29. pii: S0090-8258(20)34225.
    >> Share

  92. LIANG MI, Chen L, Hershman DL, Hillyer GC, et al
    Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
    Gynecol Oncol. 2020 Dec 27. pii: S0090-8258(20)34218.
    >> Share

  93. GHEZELAYAGH TS, Pennington KP, Norquist BM, Khasnavis N, et al
    Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
    Gynecol Oncol. 2020 Dec 26. pii: S0090-8258(20)34178.
    >> Share

  94. PHILP L, Tannenbaum S, Haber H, Saini A, et al
    Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer.
    Gynecol Oncol. 2020 Dec 23. pii: S0090-8258(20)34174.
    >> Share

  95. GUO Y, Jiang T, Ouyang L, Li X, et al
    A novel diagnostic nomogram based on serological and ultrasound findings for preoperative prediction of malignancy in patients with ovarian masses.
    Gynecol Oncol. 2020 Dec 20. pii: S0090-8258(20)34177.
    >> Share

  96. BANVILLE AC, Wouters MCA, Oberg AL, Goergen KM, et al
    Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
    Gynecol Oncol. 2020 Dec 17. pii: S0090-8258(20)34176.
    >> Share

  97. KARNEZIS AN, Chen SY, Chow C, Yang W, et al
    Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines.
    Gynecol Oncol. 2020 Dec 13. pii: S0090-8258(20)34175.
    >> Share

  98. YUE H, Li W, Chen R, Wang J, et al
    Stromal POSTN induced by TGF-beta1 facilitates the migration and invasion of ovarian cancer.
    Gynecol Oncol. 2020 Dec 11. pii: S0090-8258(20)34154.
    >> Share

  99. GOTOH O, Kiyotani K, Chiba T, Sugiyama Y, et al
    Immunogenomic landscape of gynecologic carcinosarcoma.
    Gynecol Oncol. 2020 Dec 6. pii: S0090-8258(20)34158.
    >> Share

  100. STOVER EH, Fuh K, Konstantinopoulos PA, Matulonis UA, et al
    Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Gynecol Oncol. 2020;159:887-898.
    >> Share

  101. WANG Z, Yin P, Sun Y, Na L, et al
    LGR4 maintains HGSOC cell epithelial phenotype and stem-like traits.
    Gynecol Oncol. 2020;159:839-849.
    >> Share

  102. FUH K, Mullen M, Blachut B, Stover E, et al
    Homologous recombination deficiency real-time clinical assays, ready or not?
    Gynecol Oncol. 2020;159:877-886.
    >> Share

  103. VETTER MH, Castaneda A, Khan A, O'Malley DM, et al
    A clinical classification system for grading platinum hypersensitivity reactions.
    Gynecol Oncol. 2020;159:794-798.
    >> Share

    November 2020
  104. STRAUBHAR AM, Wolf JL, Zhou MQC, Iasonos A, et al
    Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events.
    Gynecol Oncol. 2020 Nov 30. pii: S0090-8258(20)34132.
    >> Share

  105. HULSTAERT E, Morlion A, Levanon K, Vandesompele J, et al
    Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer: A systematic review.
    Gynecol Oncol. 2020 Nov 27. pii: S0090-8258(20)34129.
    >> Share

  106. WU L, Zhu J, Yin R, Wu X, et al
    Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort.
    Gynecol Oncol. 2020 Nov 26. pii: S0090-8258(20)34013.
    >> Share

  107. CONSIDINE DPC, Jia G, Shu X, Schildkraut JM, et al
    Genetically predicted circulating protein biomarkers and ovarian cancer risk.
    Gynecol Oncol. 2020 Nov 24. pii: S0090-8258(20)34127.
    >> Share

  108. CHO A, Lee SW, Park JY, Kim DY, et al
    Continued medical treatment for persistent early endometrial cancer in young women.
    Gynecol Oncol. 2020 Nov 24. pii: S0090-8258(20)34115.
    >> Share

  109. CHELARIU-RAICU A, Nick A, Urban R, Gordinier M, et al
    A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer.
    Gynecol Oncol. 2020 Nov 23. pii: S0090-8258(20)34124.
    >> Share

  110. KHATIB G, Seyfettinoglu S, Guzel AB, Gulec UK, et al
    Feasibility and rationale of a novel approach in advanced ovarian cancer surgery: Bat- shaped en-bloc total peritonectomy and total hysterectomy salpingo-oophorectomy with or without rectosigmoid resection (Sarta-Bat approach).
    Gynecol Oncol. 2020 Nov 21. pii: S0090-8258(20)34122.
    >> Share

  111. FEJZO MS, Chen HW, Anderson L, McDermott MS, et al
    Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34116.
    >> Share

  112. MORSE CB, Voillet V, Bates BM, Chiu EY, et al
    Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34117.
    >> Share

  113. RANA HQ, Kipnis L, Hehir K, Cronin A, et al
    Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34111.
    >> Share

  114. FREY MK, Chapman-Davis E, Glynn SM, Lin J, et al
    Adapting and avoiding coping strategies for women with ovarian cancer during the COVID-19 pandemic.
    Gynecol Oncol. 2020 Nov 19. pii: S0090-8258(20)34128.
    >> Share

  115. XU Y, Jia Y, Zhang Q, Du Y, et al
    Incidence and risk factors for postoperative venous thromboembolism in patients with ovarian cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2020 Nov 18. pii: S0090-8258(20)34121.
    >> Share

  116. WEEKS K, Lynch CF, West M, Carnahan R, et al
    Rural disparities in surgical care from gynecologic oncologists among Midwestern ovarian cancer patients.
    Gynecol Oncol. 2020 Nov 17. pii: S0090-8258(20)34114.
    >> Share

  117. BOERNER T, Tanner E, Filippova O, Zhou QC, et al
    Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34064.
    >> Share

  118. O'TOOLE SA, Huang Y, Norris L, Power Foley M, et al
    HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status.
    Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34112.
    >> Share

  119. CHEN F, Bailey CE, Alvarez RD, Shu XO, et al
    Adherence to treatment guidelines as a major determinant of survival disparities between black and white patients with ovarian cancer.
    Gynecol Oncol. 2020 Nov 15. pii: S0090-8258(20)34062.
    >> Share

  120. POORT H, Fenton ATHR, Thompson E, Dinardo MM, et al
    Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study.
    Gynecol Oncol. 2020 Nov 12. pii: S0090-8258(20)34056.
    >> Share

  121. KIMBLE DC, Dvergsten E, Thomeas-McEwing V, Karovic S, et al
    Evaluation of publicly available in vitro drug sensitivity models for ovarian and uterine cancer.
    Gynecol Oncol. 2020 Nov 12. pii: S0090-8258(20)34066.
    >> Share

  122. WALL JA, Meza-Perez S, Scalise CB, Katre A, et al
    Manipulating the Wnt/beta-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34053.
    >> Share

  123. WESLEY E, Uppendahl LD, Felices M, Dahl C, et al
    Cytomegalovirus and systemic inflammation at time of surgery is associated with worse outcomes in serous ovarian cancer.
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34051.
    >> Share

  124. BIZZARRI N, du Bois A, Fruscio R, De Felice F, et al
    Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34050.
    >> Share

  125. BLANC-DURAND F, Genestie C, Galende EY, Gouy S, et al
    Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape.
    Gynecol Oncol. 2020 Nov 5. pii: S0090-8258(20)33955.
    >> Share

  126. RUSSELL B, Hawarden A, Gee M, Edmondson RJ, et al
    Propensity score matching confirms that primary surgery or neoadjuvant chemotherapy result in equivalent survival within a comprehensive cohort of patients with high-grade serous ovarian cancer.
    Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34057.
    >> Share

  127. DIAZ-FEIJOO B, Bebia V, Hernandez A, Gilabert-Estalles J, et al
    Surgical complications comparing extraperitoneal vs transperitoneal laparoscopic aortic staging in early stage ovarian and endometrial cancer.
    Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34060.
    >> Share

    October 2020
  128. RUBINSTEIN MM, Grisham RN, Cadoo K, Kyi C, et al
    A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
    Gynecol Oncol. 2020 Oct 30. pii: S0090-8258(20)34041.
    >> Share

  129. ELAYAPILLAI S, Ramraj S, Benbrook DM, Bieniasz M, et al
    Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer.
    Gynecol Oncol. 2020 Oct 29. pii: S0090-8258(20)34018.
    >> Share

  130. MATSUO K, Matsuzaki S, Nusbaum DJ, Maoz A, et al
    Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.
    Gynecol Oncol. 2020 Oct 23. pii: S0090-8258(20)34049.
    >> Share

  131. CEPPI L, Grassi T, Galli F, Buda A, et al
    Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers.
    Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)34036.
    >> Share

  132. HALL MR, Dehbi HM, Banerjee S, Lord R, et al
    A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
    Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)33958.
    >> Share

  133. BARBER EL, Garg R, Persenaire C, Simon M, et al
    Natural language processing with machine learning to predict outcomes after ovarian cancer surgery.
    Gynecol Oncol. 2020 Oct 14. pii: S0090-8258(20)34012.
    >> Share

  134. MORTON M, Chambers LM, Costales AB, Chichura A, et al
    Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2020 Oct 13. pii: S0090-8258(20)33962.
    >> Share

  135. MICHELS J, Genestie C, Dunant A, Caron O, et al
    Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
    Gynecol Oncol. 2020 Oct 12. pii: S0090-8258(20)33960.
    >> Share

  136. HAUNSCHILD CE, Tewari KS
    The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
    Gynecol Oncol. 2020 Oct 11. pii: S0090-8258(20)33953.
    >> Share

  137. CARR C, Son J, Yao M, Priyadarshini A, et al
    Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
    Gynecol Oncol. 2020 Oct 9. pii: S0090-8258(20)33949.
    >> Share

  138. NICA A, Lee JYJ, Hong NL, May T, et al
    Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer.
    Gynecol Oncol. 2020 Oct 6. pii: S0090-8258(20)33961.
    >> Share

  139. CORVIGNO S, Mezheyeuski A, De La Fuente LM, Westbom-Fremer S, et al
    High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.
    Gynecol Oncol. 2020 Oct 5. pii: S0090-8258(20)33951.
    >> Share

  140. CICCONE MA, Adams CL, Bowen C, Thakur T, et al
    Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
    Gynecol Oncol. 2020 Oct 5. pii: S0090-8258(20)33950.
    >> Share

  141. UBACHS J, Koole SN, Lahaye M, Fabris C, et al
    No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
    Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33952.
    >> Share

  142. GERSHENSON DM, Cobb LP, Sun CC
    Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for the relative efficacy of tamoxifen and aromatase inhibitors.
    Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33959.
    >> Share

  143. LENTZ SE, Powell CB, Haque R, Armstrong MA, et al
    Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
    Gynecol Oncol. 2020 Oct 1. pii: S0090-8258(20)33914.
    >> Share

  144. EAKIN CM, Ewongwo A, Pendleton L, Monk BJ, et al
    Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
    Gynecol Oncol. 2020;159:112-117.
    >> Share

  145. SALANI R, Liu JF
    Meeting report from the 2020 Annual (virtual) Meeting of the American Society of Clinical Oncology.
    Gynecol Oncol. 2020;159:13-16.
    >> Share

  146. CRESTANI A, Benoit L, Touboul C, Pasquier J, et al
    Hyperthermic intraperitoneal chemotherapy (HIPEC): Should we look closer at the microenvironment?
    Gynecol Oncol. 2020;159:285-294.
    >> Share

    September 2020
  147. KOTSOPOULOS J, Gronwald J, McCuaig JM, Karlan BY, et al
    Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2020 Sep 30. pii: S0090-8258(20)33947.
    >> Share

  148. CHAN JK, Liang SY, Kapp DS, Chan JE, et al
    Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.
    Gynecol Oncol. 2020 Sep 26. pii: S0090-8258(20)33910.
    >> Share

  149. LANDOLFO C, Achten ETL, Ceusters J, Baert T, et al
    Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.
    Gynecol Oncol. 2020 Sep 26. pii: S0090-8258(20)33918.
    >> Share

  150. MIRZA MR, Benigno B, Dorum A, Mahner S, et al
    Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
    Gynecol Oncol. 2020 Sep 24. pii: S0090-8258(20)33899.
    >> Share

  151. WICHMANN C, Klotz DM, Zeiler HJ, Hilger RA, et al
    The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
    Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33911.
    >> Share

  152. MANRRIQUEZ E, Mandelbaum A, Aguayo E, Zakhour M, et al
    Factors associated with high-cost hospitalizations in elderly ovarian cancer patients.
    Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33919.
    >> Share

  153. CHARO LM, Jou J, Binder P, Hohmann SF, et al
    Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33915.
    >> Share

  154. JOHNSON KE, Popratiloff A, Fan Y, McDonald S, et al
    Analytic comparison of talc in commercially available baby powder and in pelvic tissues resected from ovarian carcinoma patients.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33921.
    >> Share

  155. EAKIN CM, Norton TJ, Monk BJ, Chase DM, et al
    Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer.
    Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33817.
    >> Share

  156. MUSORO JZ, Coens C, Greimel E, King MT, et al
    Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
    Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33900.
    >> Share

  157. BANTIE L, Tadesse S, Likisa J, Yu M, et al
    A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33905.
    >> Share

  158. GUNAY G, Kirit HA, Kamatar A, Baghdasaryan O, et al
    The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33857.
    >> Share

  159. MUSTON D, Hettle R, Monberg M, McLaurin KK, et al
    Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33814.
    >> Share

  160. KANBERGS AN, Manning-Geist BL, Pelletier A, Sullivan MW, et al
    Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer.
    Gynecol Oncol. 2020 Sep 18. pii: S0090-8258(20)33904.
    >> Share

  161. JORDAN SE, Saad H, Covarrubias AS, Siemon J, et al
    mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population.
    Gynecol Oncol. 2020 Sep 17. pii: S0090-8258(20)33831.
    >> Share

  162. CHAMBERS LM, Kuznicki M, Yao M, Chichura A, et al
    Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
    Gynecol Oncol. 2020 Sep 16. pii: S0090-8258(20)33903.
    >> Share

  163. PALMQVIST C, Staf C, Mateoiu C, Johansson M, et al
    Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment.
    Gynecol Oncol. 2020 Sep 15. pii: S0090-8258(20)33897.
    >> Share

  164. HURWITZ LM, Pinsky PF, Huang WY, Freedman ND, et al
    Aspirin use and ovarian cancer risk using extended follow-up of the PLCO Cancer Screening Trial.
    Gynecol Oncol. 2020 Sep 10. pii: S0090-8258(20)33855.
    >> Share

  165. PLETT H, Filippova OT, Garbi A, Kommoss S, et al
    Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study.
    Gynecol Oncol. 2020 Sep 9. pii: S0090-8258(20)33829.
    >> Share

  166. MADARIAGA A, Garg S, Bruce JP, Thiryayi S, et al
    Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer.
    Gynecol Oncol. 2020 Sep 7. pii: S0090-8258(20)33849.
    >> Share

  167. WALLBILLICH JJ, Morris RT, Ali-Fehmi R
    Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
    Gynecol Oncol. 2020 Sep 5. pii: S0090-8258(20)33813.
    >> Share

  168. DI DONATO V, Di Pinto A, Giannini A, Caruso G, et al
    Modified fragility index and surgical complexity score are able to predict postoperative morbidity and mortality after cytoreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2020 Sep 4. pii: S0090-8258(20)33823.
    >> Share

    August 2020
  169. SIA TY, Wen T, Cham S, Friedman AM, et al
    Effect of frailty on postoperative readmissions and cost of care for ovarian cancer.
    Gynecol Oncol. 2020 Aug 28. pii: S0090-8258(20)33825.
    >> Share

  170. GONZALEZ R, Havrilesky LJ, Myers ER, Secord AA, et al
    Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.
    Gynecol Oncol. 2020 Aug 27. pii: S0090-8258(20)33759.
    >> Share

  171. SHEN L, Xie L, Li R, Shan B, et al
    A preoperative prediction model for predicting coexisting adnexa malignancy of patients with G1/G2 endometrioid endometrial cancer.
    Gynecol Oncol. 2020 Aug 23. pii: S0090-8258(20)33818.
    >> Share

  172. BELL SG, Dalton L, McNeish BL, Fang F, et al
    Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients.
    Gynecol Oncol. 2020 Aug 23. pii: S0090-8258(20)33816.
    >> Share

  173. RICHARDSON MT, Mysona DP, Klein DA, Mann A, et al
    Long term survival outcomes of stage I mucinous ovarian cancer - A clinical calculator predictive of chemotherapy benefit.
    Gynecol Oncol. 2020 Aug 20. pii: S0090-8258(20)32386.
    >> Share

  174. AVIKI EM, Lavery JA, Roche KL, Cowan R, et al
    Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer.
    Gynecol Oncol. 2020 Aug 16. pii: S0090-8258(20)33754.
    >> Share

  175. BOERNER T, Filippova OT, Chi AJ, Iasonos A, et al
    Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study.
    Gynecol Oncol. 2020 Aug 10. pii: S0090-8258(20)33751.
    >> Share

  176. POTHURI B, O'Cearbhaill R, Eskander R, Armstrong D, et al
    Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
    Gynecol Oncol. 2020 Aug 7. pii: S0090-8258(20)33747.
    >> Share

  177. POWELL CB, Laurent C, Ciaravino G, Garcia C, et al
    Streamlining genetic testing for women with ovarian cancer in a Northern California health care system.
    Gynecol Oncol. 2020 Aug 7. pii: S0090-8258(20)33662.
    >> Share

  178. BEESLEY VL, Webber K, Nagle CM, DeFazio A, et al
    When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer.
    Gynecol Oncol. 2020 Aug 6. pii: S0090-8258(20)33664.
    >> Share

  179. LEE EK, Xiong N, Cheng SC, Barry WT, et al
    Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
    Gynecol Oncol. 2020 Aug 5. pii: S0090-8258(20)33663.
    >> Share

    July 2020
  180. LEE JM, Annunziata CM, Hays JL, Cao L, et al
    Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.
    Gynecol Oncol. 2020 Jul 31. pii: S0090-8258(20)33677.
    >> Share

  181. COLOMBO N, Oza AM, Lorusso D, Aghajanian C, et al
    The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
    Gynecol Oncol. 2020 Jul 31. pii: S0090-8258(20)31130.
    >> Share

  182. TEWARI KS, Sill MW, Coleman RL, Aghajanian C, et al
    Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)32390.
    >> Share

  183. SCHWARTZ GG, Tretli S, Klug MG, Robsahm TE, et al
    Women who develop ovarian cancer show an increase in serum calcium and a decrease in serum albumin. A longitudinal study in the Janus Serum Bank Cohort.
    Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)32381.
    >> Share

  184. BLANC-DURAND F, Lefeuvre-Plesse C, Ray-Coquard I, Chaltiel D, et al
    Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT).
    Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)33654.
    >> Share

  185. ROBELIN P, Tod M, Colomban O, Lachuer J, et al
    Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
    Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)33656.
    >> Share

  186. FALCONER H, Joneborg U, Krawiec K, Palsdottir K, et al
    Ultra-radical upfront surgery does not improve survival in women with advanced epithelial ovarian cancer; a natural experiment in a complete population.
    Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)32384.
    >> Share

  187. ANGELES MA, Rychlik A, Cabarrou B, Spagnolo E, et al
    A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
    Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)32321.
    >> Share

  188. COBB LP, Sun CC, Iyer R, Nick AM, et al
    The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
    Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)32324.
    >> Share

  189. WEISS AS, Swisher E, Pennington KP, Radke M, et al
    Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years.
    Gynecol Oncol. 2020 Jul 21. pii: S0090-8258(20)32335.
    >> Share

  190. LORUSSO D, Marchetti C, Conte C, Giudice E, et al
    Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study.
    Gynecol Oncol. 2020 Jul 20. pii: S0090-8258(20)33657.
    >> Share

  191. TAYLAN E, Zayou F, Murali R, Karlan BY, et al
    Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model.
    Gynecol Oncol. 2020 Jul 19. pii: S0090-8258(20)32380.
    >> Share

  192. WU JL, Zhao J, Zhang HB, Zuo WW, et al
    Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer.
    Gynecol Oncol. 2020 Jul 18. pii: S0090-8258(20)32387.
    >> Share

  193. ZHENG L, Cui C, Shi O, Lu X, et al
    Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990-2017.
    Gynecol Oncol. 2020 Jul 18. pii: S0090-8258(20)32383.
    >> Share

  194. MCCUAIG JM, Care M, Ferguson SE, Kim RH, et al
    Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.
    Gynecol Oncol. 2020 Jul 13. pii: S0090-8258(20)32333.
    >> Share

  195. ROSS TL, DeFazio A, Friedlander M, Grant P, et al
    Insomnia and its association with quality of life in women with ovarian cancer.
    Gynecol Oncol. 2020 Jul 9. pii: S0090-8258(20)32326.
    >> Share

  196. PRESSEY JG, Dandoy CE, Pater LE, Sroga Rios J, et al
    Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): Comprehensive management of a newly diagnosed young adult.
    Gynecol Oncol. 2020 Jul 9. pii: S0090-8258(20)31975.
    >> Share

  197. BERNARD L, Boucher J, Helpman L
    Bowel resection or repair at the time of cytoreductive surgery for ovarian malignancy is associated with increased complication rate: An ACS-NSQIP study.
    Gynecol Oncol. 2020 Jul 6. pii: S0090-8258(20)32330.
    >> Share

  198. BRIEGER KK, Peterson S, Lee AW, Mukherjee B, et al
    Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival.
    Gynecol Oncol. 2020 Jul 5. pii: S0090-8258(20)32296.
    >> Share

  199. DERQUIN F, Floquet A, Hardy-Bessard AC, Edeline J, et al
    Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.
    Gynecol Oncol. 2020 Jul 2. pii: S0090-8258(20)32315.
    >> Share

  200. BAE-JUMP V
    Unraveling the mystery of clear cell endometrial cancer.
    Gynecol Oncol. 2020;158:1-2.
    >> Share

    June 2020
  201. JONES TL, Sandler CX, Spence RR, Hayes SC, et al
    Physical activity and exercise in women with ovarian cancer: A systematic review.
    Gynecol Oncol. 2020 Jun 29. pii: S0090-8258(20)32300.
    >> Share

  202. LAGO V, Fotopoulou C, Chiantera V, Minig L, et al
    Indications and practice of diverting ileostomy after colorectal resection and anastomosis in ovarian cancer cytoreduction.
    Gynecol Oncol. 2020 Jun 19. pii: S0090-8258(20)31132.
    >> Share

  203. SIMPSON AN, Sutradhar R, Ferguson SE, Robertson D, et al
    Perioperative outcomes of women with and without class III obesity undergoing hysterectomy for endometrioid endometrial cancer: A population-based study.
    Gynecol Oncol. 2020 Jun 19. pii: S0090-8258(20)32295.
    >> Share

  204. MARIA S, Faron M, Maulard A, Pautier P, et al
    Long term follow-up of a large series of stage-II/III atypical proliferative serous ovarian tumors.
    Gynecol Oncol. 2020 Jun 19. pii: S0090-8258(20)32304.
    >> Share

  205. DILLEY J, Burnell M, Gentry-Maharaj A, Ryan A, et al
    Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Gynecol Oncol. 2020 Jun 16. pii: S0090-8258(20)31029.
    >> Share

  206. NICA A, Covens A, Parra-Herran C, May T, et al
    Does timing of intraperitoneal chemotherapy initiation following primary cytoreductive surgery with bowel resection impact outcomes in patients with advanced ovarian cancer?
    Gynecol Oncol. 2020 Jun 16. pii: S0090-8258(20)32293.
    >> Share

  207. PYRZAK A, Chen L, Kocherginsky M, Barber EL, et al
    Radiation and hormonal therapy for primary treatment of stage I endometrial cancer and long-term survival.
    Gynecol Oncol. 2020 Jun 16. pii: S0090-8258(20)31088.
    >> Share

  208. MARCHETTI C, Minucci A, D'Indinosante M, Ergasti R, et al
    Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach.
    Gynecol Oncol. 2020 Jun 15. pii: S0090-8258(20)32294.
    >> Share

  209. MOORE KN, Birrer MJ, Marsters J, Wang Y, et al
    Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2020 Jun 11. pii: S0090-8258(20)31124.
    >> Share

  210. NARASIMHULU DM, McGree ME, Weaver AL, Jatoi A, et al
    Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer.
    Gynecol Oncol. 2020 Jun 6. pii: S0090-8258(20)31131.
    >> Share

  211. BOGANI G, Lopez S, Mantiero M, Ducceschi M, et al
    Immunotherapy for platinum-resistant ovarian cancer.
    Gynecol Oncol. 2020 Jun 6. pii: S0090-8258(20)31924.
    >> Share

  212. STRAUBHAR AM, Filippova OT, Cowan RA, Lakhman Y, et al
    A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative.
    Gynecol Oncol. 2020 Jun 6. pii: S0090-8258(20)31126.
    >> Share

  213. HAMILTON E, O'Malley DM, O'Cearbhaill R, Cristea M, et al
    Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
    Gynecol Oncol. 2020 Jun 5. pii: S0090-8258(20)31123.
    >> Share

  214. MORRISON A, Nasioudis D
    Reproductive outcomes following fertility-sparing surgery for malignant ovarian germ cell tumors: A systematic review of the literature.
    Gynecol Oncol. 2020 Jun 5. pii: S0090-8258(20)31121.
    >> Share

  215. VENERIS JT, Mahajan P, Frazier AL
    Contemporary management of ovarian germ cell tumors and remaining controversies.
    Gynecol Oncol. 2020 Jun 4. pii: S0090-8258(20)31075.
    >> Share

  216. ARMEL SR, Volenik A, Demsky R, Malcolmson J, et al
    Setting a baseline: A 7-year review of referral rates and outcomes for serous ovarian cancer prior to implementation of oncologist mediated genetic testing.
    Gynecol Oncol. 2020 Jun 3. pii: S0090-8258(20)31082.
    >> Share

  217. BOLAND JL, Zhou Q, Iasonos AE, O'Cearbhaill RE, et al
    Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy.
    Gynecol Oncol. 2020 Jun 2. pii: S0090-8258(20)31073.
    >> Share

  218. ROCHE KL, Chi DS
    Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big reward...or too much risk?
    Gynecol Oncol. 2020;157:561-562.
    >> Share

  219. CHAMBERS LM, Pendlebury A, Rose PG, Yao M, et al
    Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer.
    Gynecol Oncol. 2020 Jun 1. pii: S0090-8258(20)31018.
    >> Share

  220. CHEN H, Gotimer K, De Souza C, Tepper CG, et al
    Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma.
    Gynecol Oncol. 2020;157:783-792.
    >> Share

  221. DUSKA LR, Petroni GR, Varhegyi N, Brown J, et al
    A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
    Gynecol Oncol. 2020;157:585-592.
    >> Share

    May 2020
  222. KNISELY A, Huang Y, Melamed A, Tergas AI, et al
    Travel distance, hospital volume and their association with ovarian cancer short- and long-term outcomes.
    Gynecol Oncol. 2020 May 23. pii: S0090-8258(20)31085.
    >> Share

  223. GLEESON M, Kentwell M, Meiser B, Do J, et al
    The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients.
    Gynecol Oncol. 2020 May 22. pii: S0090-8258(20)31028.
    >> Share

  224. SMAZYNSKI J, Hamilton PT, Thornton S, Milne K, et al
    The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
    Gynecol Oncol. 2020 May 20. pii: S0090-8258(20)30989.
    >> Share

  225. MATSUO K, Chang EJ, Matsuzaki S, Mandelbaum RS, et al
    Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes.
    Gynecol Oncol. 2020 May 10. pii: S0090-8258(20)30304.
    >> Share

  226. LUO S, Zhang Y, Yang Y, Zhu S, et al
    Clonal tumor mutations in homologous recombination genes predict favorable clinical outcome in ovarian cancer treated with platinum-based chemotherapy.
    Gynecol Oncol. 2020 May 8. pii: S0090-8258(20)30995.
    >> Share

  227. BOUCHARD-FORTIER G, Cusimano MC, Fazelzad R, Sajewycz K, et al
    Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 May 6. pii: S0090-8258(20)30259.
    >> Share

  228. SIVAKUMARAN T, Mileshkin L, Grant P, Na L, et al
    Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.
    Gynecol Oncol. 2020 May 4. pii: S0090-8258(20)31016.
    >> Share

  229. DAI Y, Wang Z, Wang J
    Survival of microsatellite-stable endometrioid endometrial cancer patients after minimally invasive surgery: An analysis of the Cancer Genome Atlas data.
    Gynecol Oncol. 2020 May 4. pii: S0090-8258(20)30984.
    >> Share

  230. SONG F, Li L, Zhang B, Zhao Y, et al
    Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
    Gynecol Oncol. 2020 May 1. pii: S0090-8258(20)30988.
    >> Share

    April 2020
  231. STAPLES JN, Peres LC, Camacho F, Alberg AJ, et al
    Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES).
    Gynecol Oncol. 2020 Apr 30. pii: S0090-8258(20)31010.
    >> Share

  232. MONK BJ, Coleman RL, Moore KN, Herzog TJ, et al
    COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies.
    Gynecol Oncol. 2020 Apr 29. pii: S0090-8258(20)31013.
    >> Share

  233. CHEN Y, Li G
    Gynecological malignancies with asymptomatic SARS-CoV-2 infection during the convalescence of outbreak.
    Gynecol Oncol. 2020 Apr 29. pii: S0090-8258(20)31019.
    >> Share

  234. NASIOUDIS D, Ko EM, Haggerty AF, Cory L, et al
    Performance of lymphadenectomy for apparent early stage malignant ovarian germ cell tumors in the era of platinum-based chemotherapy.
    Gynecol Oncol. 2020 Apr 28. pii: S0090-8258(20)30306.
    >> Share

  235. SEARLE G, Pounds R, Phillips A, Kehoe S, et al
    Prolonged interruption of chemotherapy in patients undergoing delayed debulking surgery for advanced high grade serous ovarian cancer is associated with a worse prognosis.
    Gynecol Oncol. 2020 Apr 25. pii: S0090-8258(20)30307.
    >> Share

  236. MAJIDI A, Na R, Dixon-Suen S, Jordan SJ, et al
    Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Apr 18. pii: S0090-8258(20)30253.
    >> Share

  237. HOOGSTAD-VAN EVERT JS, Bekkers R, Ottevanger N, Jansen JH, et al
    Harnessing natural killer cells for the treatment of ovarian cancer.
    Gynecol Oncol. 2020 Apr 5. pii: S0090-8258(20)30236.
    >> Share

  238. AREND RC, Beer HM, Cohen YC, Berlin S, et al
    Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.
    Gynecol Oncol. 2020 Apr 5. pii: S0090-8258(20)30180.
    >> Share

  239. NARASIMHULU DM, Kumar A, Weaver AL, Langstraat CL, et al
    Less guessing, more evidence in identifying patients least fit for cytoreductive surgery in advanced ovarian cancer: A triage algorithm to individualize surgical management.
    Gynecol Oncol. 2020 Apr 1. pii: S0090-8258(20)30249.
    >> Share

  240. CHEVROT A, Pouget N, Bats AS, Huchon C, et al
    Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group.
    Gynecol Oncol. 2020;157:29-35.
    >> Share

  241. SCOTT SA, Llaurado Fernandez M, Kim H, Elit L, et al
    Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.
    Gynecol Oncol. 2020;157:36-45.
    >> Share

  242. MUELLER JJ, Pedra Nobre S, Braxton K, Alektiar KM, et al
    Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma.
    Gynecol Oncol. 2020 Apr 1. pii: S0090-8258(20)30250.
    >> Share

    March 2020
  243. BENNETSEN AKK, Baandrup L, Aalborg GL, Kjaer SK, et al
    Non-epithelial ovarian cancer in Denmark - Incidence and survival over nearly 40years.
    Gynecol Oncol. 2020 Mar 26. pii: S0090-8258(20)30246.
    >> Share

  244. GONZALEZ R, Gockley AA, Melamed A, Sugrue R, et al
    Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer.
    Gynecol Oncol. 2020 Mar 25. pii: S0090-8258(20)30228.
    >> Share

  245. RUSH SK, Swisher EM, Garcia RL, Pennington KP, et al
    Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
    Gynecol Oncol. 2020 Mar 19. pii: S0090-8258(20)30101.
    >> Share

  246. BETELLA I, Turbitt WJ, Szul T, Wu B, et al
    Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer.
    Gynecol Oncol. 2020 Mar 16. pii: S0090-8258(20)30226.
    >> Share

  247. WOLFORD JE, Bai J, Moore KN, Kristeleit R, et al
    Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
    Gynecol Oncol. 2020 Mar 13. pii: S0090-8258(20)30176.
    >> Share

  248. LIONTOS M, Sotiropoulou M, Kaparelou M, Tzannis K, et al
    Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy.
    Gynecol Oncol. 2020 Mar 12. pii: S0090-8258(20)30224.
    >> Share

  249. ROZE JF, Veldhuis WB, Hoogendam JP, Verheijen RHM, et al
    Prognostic value of radiological recurrence patterns in ovarian cancer.
    Gynecol Oncol. 2020 Mar 11. pii: S0090-8258(20)30219.
    >> Share

  250. VAN WALREE IC, Bretveld R, van Huis-Tanja LH, Louwers JA, et al
    Reasons for guideline non-adherence in older and younger women with advanced stage ovarian cancer.
    Gynecol Oncol. 2020 Mar 11. pii: S0090-8258(20)30221.
    >> Share

  251. LEVY T, Migdan Z, Aleohin N, Ben-Shem, et al
    Retroperitoneal lymph node recurrence of epithelial ovarian cancer: Prognostic factors and treatment outcome.
    Gynecol Oncol. 2020 Mar 6. pii: S0090-8258(20)30158.
    >> Share

  252. HAQUE R, Skates SJ, Armstrong MA, Lentz SE, et al
    Feasibility, patient compliance and acceptability of ovarian cancer surveillance using two serum biomarkers and Risk of Ovarian Cancer Algorithm compared to standard ultrasound and CA 125 among women with BRCA mutations.
    Gynecol Oncol. 2020 Mar 4. pii: S0090-8258(20)30164.
    >> Share

  253. PIERSON WE, Peters PN, Chang MT, Chen LM, et al
    An integrated molecular profile of endometrioid ovarian cancer.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30144.
    >> Share

  254. GONTHIER C, Douhnai D, Koskas M
    Lymph node metastasis probability in young patients eligible for conservative management of endometrial cancer.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30157.
    >> Share

  255. REINHOLDT K, Kjaer SK, Guleria S, Frederiksen K, et al
    Risk of endometrial cancer among women with benign ovarian tumors - A Danish nationwide cohort study.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30178.
    >> Share

  256. MOORE KN, Zorn KK
    Germline and Somatic Testing in Ovarian Cancer: Shifting Sands of Recommendations.
    Gynecol Oncol. 2020;156:515-516.
    >> Share

  257. POWELL CB, Littell RD, Landen CN Jr, Pramanik S, et al
    Cytological sampling of fallopian tubes using a hysteroscopic catheter: A multi-center study.
    Gynecol Oncol. 2020;156:636-640.
    >> Share

  258. LENCK C, Chopin N, Gouy S, Bonsang-Kitzis H, et al
    The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study.
    Gynecol Oncol. 2020 Mar 1. pii: S0090-8258(20)30145.
    >> Share

    February 2020
  259. CHANG CP, Chen Y, Blackburn B, Abdelaziz S, et al
    Genitourinary disease risks among ovarian cancer survivors in a population-based cohort study.
    Gynecol Oncol. 2020 Feb 28. pii: S0090-8258(20)30162.
    >> Share

  260. PLETT H, Harter P, Ataseven B, Heitz F, et al
    Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors.
    Gynecol Oncol. 2020 Feb 27. pii: S0090-8258(20)30102.
    >> Share

  261. GLASER GE, Kalogera E, Kumar A, Yi J, et al
    Outcomes and patient perspectives following implementation of tiered opioid prescription guidelines in gynecologic surgery.
    Gynecol Oncol. 2020 Feb 24. pii: S0090-8258(20)30161.
    >> Share

  262. PRAISS AM, Huang Y, St Clair CM, Tergas AI, et al
    A modern assessment of the surgical pathologic spread and nodal dissemination of endometrial cancer.
    Gynecol Oncol. 2020 Feb 21. pii: S0090-8258(20)30150.
    >> Share

  263. O'MALLEY DM, Matulonis UA, Birrer MJ, Castro CM, et al
    Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    Gynecol Oncol. 2020 Feb 18. pii: S0090-8258(20)30090.
    >> Share

  264. UEHARA T, Yoshida H, Fukuhara M, Yoshida M, et al
    Efficacy of ascitic fluid cell block for diagnosing primary ovarian, peritoneal, and tubal cancer in patients with peritoneal carcinomatosis with ascites.
    Gynecol Oncol. 2020 Feb 13. pii: S0090-8258(20)30099.
    >> Share

  265. FREY MK, Lee SS, Gerber D, Schwartz ZP, et al
    Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression.
    Gynecol Oncol. 2020 Feb 11. pii: S0090-8258(20)30007.
    >> Share

  266. PETERSEN S, Wilson AJ, Hirst J, Roby KF, et al
    CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
    Gynecol Oncol. 2020 Feb 7. pii: S0090-8258(20)30091.
    >> Share

  267. PIAO J, Lee EJ, Lee M
    Association between pelvic inflammatory disease and risk of ovarian cancer: An updated meta-analysis.
    Gynecol Oncol. 2020 Feb 6. pii: S0090-8258(20)30097.
    >> Share

  268. COLEMAN RL, Handley KF, Burger R, Molin GZD, et al
    Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
    Gynecol Oncol. 2020 Feb 6. pii: S0090-8258(20)30095.
    >> Share

  269. ROJAS C, Tian C, Powell MA, Chan JK, et al
    Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival.
    Gynecol Oncol. 2020 Feb 3. pii: S0090-8258(20)30057.
    >> Share

  270. SOLSKY I, Chen J, Rebbeck TR
    Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.
    Gynecol Oncol. 2020;156:363-376.
    >> Share

  271. DOGAN NU, Dogan S, Erol M, Uzun BT, et al
    Cisterna chyli: An important landmark in laparoscopic paraaortic lymphadenectomy.
    Gynecol Oncol. 2020;156:511.
    >> Share

  272. VENERIS JT, Matulonis UA, Liu JF, Konstantinopoulos PA, et al
    Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.
    Gynecol Oncol. 2020;156:488-497.
    >> Share

    January 2020
  273. KORENAGA TR, Ward KK, Saenz C, McHale MT, et al
    The elevated risk of ovarian clear cell carcinoma among Asian Pacific Islander women in the United States is not affected by birthplace.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30086.
    >> Share

  274. SIEMON J, Galli J, Slomovitz B, Schlumbrecht M, et al
    Disparities in care among patients with low-grade serous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(19)31871.
    >> Share

  275. NASIOUDIS D, Mastroyannis SA, Latif NA, Ko EM, et al
    Trends in the surgical management of malignant ovarian germ-cell tumors.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30087.
    >> Share

  276. CABASAG CJ, Butler J, Arnold M, Rutherford M, et al
    Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study.
    Gynecol Oncol. 2020 Jan 28. pii: S0090-8258(19)31877.
    >> Share

  277. XUE C, Xu Y, Ye W, Xie Q, et al
    Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor.
    Gynecol Oncol. 2020 Jan 24. pii: S0090-8258(19)31804.
    >> Share

  278. STEWART LM, Stewart CJR, Spilsbury K, Cohen PA, et al
    Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma.
    Gynecol Oncol. 2020 Jan 23. pii: S0090-8258(20)30080.
    >> Share

  279. HAVRILESKY LJ, Lim S, Ehrisman JA, Lorenzo A, et al
    Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
    Gynecol Oncol. 2020 Jan 22. pii: S0090-8258(20)30070.
    >> Share

  280. BOGANI G, Ditto A, Lopez S, Bertolina F, et al
    Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Jan 21. pii: S0090-8258(19)31875.
    >> Share

  281. SLOMOVITZ B, Gourley C, Carey MS, Malpica A, et al
    Low-grade serous ovarian cancer: State of the science.
    Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(19)31862.
    >> Share

  282. FEKETE JT, Osz A, Pete I, Nagy GR, et al
    Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.
    Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(20)30006.
    >> Share

  283. CADOO KA, Grisham RN, O'Cearbhaill RE, Boucicaut NN, et al
    A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
    Gynecol Oncol. 2020 Jan 17. pii: S0090-8258(20)30060.
    >> Share

  284. NASIOUDIS D, Frey MK, Chapman-Davis E, Caputo TA, et al
    Primary malignant ovarian carcinoid; management and outcomes.
    Gynecol Oncol. 2020 Jan 17. pii: S0090-8258(20)30002.
    >> Share

  285. ACOSTA-TORRES S, Fader AN
    Laparoscopic splenectomy for secondary cytoreduction of ovarian cancer in a woman with localized splenic recurrence.
    Gynecol Oncol. 2020 Jan 16. pii: S0090-8258(19)31842.
    >> Share

  286. MERIDETH MA, Harney LA, Vyas N, Bachi A, et al
    Gynecologic and reproductive health in patients with pathogenic germline variants in DICER1.
    Gynecol Oncol. 2020 Jan 15. pii: S0090-8258(19)31867.
    >> Share

  287. GHIRARDI V, Moruzzi MC, Bizzarri N, Vargiu V, et al
    Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Gynecol Oncol. 2020 Jan 14. pii: S0090-8258(20)30017.
    >> Share

  288. LLAURADO FERNANDEZ M, Dawson A, Kim H, Lam N, et al
    Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 14. pii: S0090-8258(19)31680.
    >> Share

  289. BEAVIS AL, Yen TT, Stone RL, Wethington SL, et al
    Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?
    Gynecol Oncol. 2020 Jan 13. pii: S0090-8258(19)31849.
    >> Share

  290. BIXEL K, Vetter M, Davidson B, Berchuck A, et al
    Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2020 Jan 11. pii: S0090-8258(19)31837.
    >> Share

  291. MORGAN RD, Banerjee S, Hall M, Clamp AR, et al
    Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30005.
    >> Share

  292. STALEY SA, Tucker K, Newton M, Ertel M, et al
    Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30003.
    >> Share

  293. RAFFONE A, Travaglino A, Mascolo M, Carotenuto C, et al
    Histopathological characterization of ProMisE molecular groups of endometrial cancer.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30008.
    >> Share

  294. WANG D, Zhu S, Jia C, Cao D, et al
    Diagnosis and management of growing teratoma syndrome after ovarian immature teratoma: A single center experience.
    Gynecol Oncol. 2020 Jan 9. pii: S0090-8258(19)31872.
    >> Share

  295. MONK BJ, Herzog TJ, Wang G, Triantos S, et al
    A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
    Gynecol Oncol. 2020 Jan 8. pii: S0090-8258(19)31873.
    >> Share

  296. FRAUNE C, Rosebrock J, Simon R, Hube-Magg C, et al
    High homogeneity of MMR deficiency in ovarian cancer.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31861.
    >> Share

  297. SIAMAKPOUR-REIHANI S, Cobb LP, Jiang C, Zhang D, et al
    Differential expression of immune related genes in high-grade ovarian serous carcinoma.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31840.
    >> Share

  298. PEIRETTI M, Candotti G, Fais ML, Ricciardi E, et al
    Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31870.
    >> Share

  299. BREWER M, Angioli R, Scambia G, Lorusso D, et al
    Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study.
    Gynecol Oncol. 2020 Jan 6. pii: S0090-8258(19)31845.
    >> Share

  300. GORRINGE KL, Cheasley D, Wakefield MJ, Ryland GL, et al
    Therapeutic options for mucinous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 2. pii: S0090-8258(19)31836.
    >> Share

  301. VARGHESE A, Shih IM
    Not All Peritoneal Implants Are Created Equal.
    Gynecol Oncol. 2020;156:1-2.
    >> Share

  302. CHODAVADIA PA, Jacobs CD, Wang F, Havrilesky LJ, et al
    Off-study utilization of experimental therapies: Analysis of GOG249-eligible cohorts using real world data.
    Gynecol Oncol. 2020;156:154-161.
    >> Share

  303. MHAWECH-FAUCEGLIA P, Izevbaye I, Spindler T, Wang G, et al
    Genomic heterogeneity in peritoneal implants: A differential analysis of gene expression using nanostring Human Cancer Reference panel identifies a malignant signature.
    Gynecol Oncol. 2020;156:6-12.
    >> Share

    December 2019
  304. SALMINEN L, Nadeem N, Jain S, Grenman S, et al
    A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.
    Gynecol Oncol. 2019 Dec 27. pii: S0090-8258(19)31846.
    >> Share

  305. JORGE S, McFaddin AS, Doll KM, Pennington KP, et al
    Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
    Gynecol Oncol. 2019 Dec 27. pii: S0090-8258(19)31802.
    >> Share

  306. WAMBECKE A, Ahmad M, Lambert B, Joly F, et al
    The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer.
    Gynecol Oncol. 2019 Dec 26. pii: S0090-8258(19)31841.
    >> Share

  307. KAY AH, Venn M, Urban R, Gray HJ, et al
    Postoperative narcotic use in patients with ovarian cancer on an Enhanced Recovery After Surgery (ERAS) pathway.
    Gynecol Oncol. 2019 Dec 24. pii: S0090-8258(19)31839.
    >> Share

  308. JONES NL, Xiu J, Rocconi RP, Herzog TJ, et al
    Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.
    Gynecol Oncol. 2019 Dec 24. pii: S0090-8258(19)31694.
    >> Share

  309. CONNOR YD, Miao D, Lin DI, Hayne C, et al
    Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.
    Gynecol Oncol. 2019 Dec 21. pii: S0090-8258(19)31618.
    >> Share

  310. AREND RC, Davis AM, Chimiczewski P, O'Malley DM, et al
    EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low g
    Gynecol Oncol. 2019 Dec 20. pii: S0090-8258(19)31786.
    >> Share

  311. MATSUO K, Machida H, Matsuzaki S, Grubbs BH, et al
    Evolving population-based statistics for rare epithelial ovarian cancers.
    Gynecol Oncol. 2019 Dec 18. pii: S0090-8258(19)31781.
    >> Share

  312. NAUMANN RW, Coleman RL, Brown J, Moore KN, et al
    Corrigendum to "Phase III trials in ovarian cancer: The evolving landscape of front line therapy" [Gynecol. Oncol. 153 (2019) 436-444].
    Gynecol Oncol. 2019 Dec 16. pii: S0090-8258(19)31799.
    >> Share

  313. KRILL L, Deng W, Eskander R, Mutch D, et al
    Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
    Gynecol Oncol. 2019 Dec 13. pii: S0090-8258(19)31795.
    >> Share

  314. NASIOUDIS D, Latif NA, Simpkins F, Cory L, et al
    Adjuvant chemotherapy for early stage endometrioid ovarian carcinoma: An analysis of the National Cancer Data Base.
    Gynecol Oncol. 2019 Dec 13. pii: S0090-8258(19)31784.
    >> Share

  315. ZHANG H, Wu X, Xu Z, Sun Z, et al
    Impact of perioperative red blood cell transfusion on postoperative recovery and long-term outcome in patients undergoing surgery for ovarian cancer: A propensity score-matched analysis.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31798.
    >> Share

  316. PERES LC, Sinha S, Townsend MK, Fridley BL, et al
    Predictors of survival trajectories among women with epithelial ovarian cancer.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31803.
    >> Share

  317. ZHANG W, Tan C, Xu M, Wu X, et al
    Primary appendiceal mucinous neoplasm: Gynecological manifestations, management, and prognosis.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31681.
    >> Share

  318. KRIMMEL-MORRISON JD, Ghezelayagh TS, Lian S, Zhang Y, et al
    Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31783.
    >> Share

  319. RONCOLATO FT, O'Connell RL, Joly F, Lanceley A, et al
    Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(>/=3) chemotherapy - The GCIG symptom
    Gynecol Oncol. 2019 Dec 10. pii: S0090-8258(19)31558.
    >> Share

  320. VERGOTE I, Bergfeldt K, Franquet A, Lisyanskaya AS, et al
    A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel.
    Gynecol Oncol. 2019 Dec 9. pii: S0090-8258(19)31685.
    >> Share

  321. GITTO SB, Kim H, Rafail S, Omran DK, et al
    An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.
    Gynecol Oncol. 2019 Dec 6. pii: S0090-8258(19)31568.
    >> Share

  322. FORSSE D, Tangen IL, Fasmer KE, Halle MK, et al
    Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling.
    Gynecol Oncol. 2019 Dec 5. pii: S0090-8258(19)31782.
    >> Share

  323. HINCHCLIFF E, Jazaeri AA
    Sunset, or dawn of a new age for ovarian cancer vaccine therapy?
    Gynecol Oncol. 2019;155:387-388.
    >> Share

    November 2019
  324. VERGOTE I, Heitz F, Buderath P, Powell M, et al
    A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2019 Nov 29. pii: S0090-8258(19)31627.
    >> Share

  325. TAKAYA H, Nakai H, Sakai K, Nishio K, et al
    Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course.
    Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31664.
    >> Share

  326. NARASIMHULU DM, Bews KA, Hanson KT, Chang YH, et al
    Using evidence to direct quality improvement efforts: Defining the highest impact complications after complex cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31628.
    >> Share

  327. MATSUO K, Machida H, Grubbs BH, Matsuzaki S, et al
    Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.
    Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31482.
    >> Share

  328. KIM J, Cho YJ, Ryu JY, Hwang I, et al
    CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer.
    Gynecol Oncol. 2019 Nov 24. pii: S0090-8258(19)31625.
    >> Share

  329. COLLINS A, Miles GJ, Wood J, MacFarlane M, et al
    Patient-derived explants, xenografts and organoids: 3-dimensional patient-relevant pre-clinical models in endometrial cancer.
    Gynecol Oncol. 2019 Nov 22. pii: S0090-8258(19)31671.
    >> Share

  330. MAI PL, Huang HQ, Wenzel LB, Han PK, et al
    Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study.
    Gynecol Oncol. 2019 Nov 21. pii: S0090-8258(19)31613.
    >> Share

  331. STASENKO M, Tunnage I, Ashley CW, Rubinstein MM, et al
    Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
    Gynecol Oncol. 2019 Nov 19. pii: S0090-8258(19)31615.
    >> Share

  332. LE PAGE C, Rahimi K, Rodrigues M, Heinzelmann-Schwarz V, et al
    Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
    Gynecol Oncol. 2019 Nov 18. pii: S0090-8258(19)31670.
    >> Share

  333. RODRIGUEZ-FREIXINOS V, Farinas-Madrid L, Gil-Martin M, Barretina-Ginesta P, et al
    Corrigendum to 'Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients' [Gynecologic Oncology 152 (2019) 270-277].
    Gynecol Oncol. 2019 Nov 16. pii: S0090-8258(19)31604.
    >> Share

  334. TAYLOR SE, Chu T, Elvin JA, Edwards RP, et al
    Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer.
    Gynecol Oncol. 2019 Nov 15. pii: S0090-8258(19)31616.
    >> Share

  335. NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
    Learning curve of high-complexity surgery for advanced ovarian cancer.
    Gynecol Oncol. 2019 Nov 14. pii: S0090-8258(19)31621.
    >> Share

  336. GAGNO S, Poletto E, Bartoletti M, Quartuccio L, et al
    A TGF-beta associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer.
    Gynecol Oncol. 2019 Nov 8. pii: S0090-8258(19)31603.
    >> Share

  337. MOORE KN, Miller A, Bell-McGuinn KM, Schilder RJ, et al
    A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
    Gynecol Oncol. 2019 Nov 7. pii: S0090-8258(19)31569.
    >> Share

  338. ALIMUJIANG A, Khoja L, Wiensch A, Pike MC, et al
    "I am not a statistic" ovarian cancer survivors' views of factors that influenced their long-term survival.
    Gynecol Oncol. 2019 Nov 6. pii: S0090-8258(19)31564.
    >> Share

  339. FEHNIGER JE, Berger AA, Juckett L, Elvin J, et al
    Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility.
    Gynecol Oncol. 2019 Nov 5. pii: S0090-8258(19)31561.
    >> Share

  340. CECERE SC, Giannone G, Salutari V, Arenare L, et al
    Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
    Gynecol Oncol. 2019 Nov 4. pii: S0090-8258(19)31607.
    >> Share

  341. BEIRNE JP, McArt DG, Roddy A, McDermott C, et al
    Defining the molecular evolution of extrauterine high grade serous carcinoma.
    Gynecol Oncol. 2019;155:305-317.
    >> Share

  342. ONG PY, Poon SL, Tan KT, Putti TC, et al
    Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
    Gynecol Oncol. 2019;155:275-279.
    >> Share

    October 2019
  343. O'CEARBHAILL RE, Deng W, Chen LM, Lucci JA 3rd, et al
    A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: A
    Gynecol Oncol. 2019 Oct 22. pii: S0090-8258(19)31536.
    >> Share

  344. ALLDREDGE J, Serna-Gallegos T, Gallegos N, VanLeer JP, et al
    Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival.
    Gynecol Oncol. 2019 Oct 22. pii: S0090-8258(19)31565.
    >> Share

  345. TATEBE K, Hasan Y, Son CH
    Adjuvant vaginal brachytherapy and chemotherapy versus pelvic radiotherapy in early-stage endometrial cancer: Outcomes by risk factors.
    Gynecol Oncol. 2019 Oct 11. pii: S0090-8258(19)31541.
    >> Share

  346. MARCHETTI C, Rosati A, Scaletta G, Pietragalla A, et al
    Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
    Gynecol Oncol. 2019 Oct 9. pii: S0090-8258(19)31545.
    >> Share

  347. BERG T, Nottrup TJ, Roed H
    Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31547.
    >> Share

  348. LABIDI-GALY SI, de La Motte Rouge T, Derbel O, Wolfer A, et al
    Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31528.
    >> Share

  349. KURODA T, Ogiwara H, Sasaki M, Takahashi K, et al
    Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31559.
    >> Share

    September 2019
  350. WONG JWH, Killeen JL, Carney ME
    Completeness of salpingectomy intended for ovarian cancer risk reduction.
    Gynecol Oncol. 2019 Sep 12. pii: S0090-8258(19)31523.
    >> Share

  351. DOCKERY LE, Rubenstein AR, Ding K, Mashburn SG, et al
    Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2019 Sep 12. pii: S0090-8258(19)31394.
    >> Share

  352. HIMOTO Y, Cybulska P, Shitano F, Sala E, et al
    Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer?
    Gynecol Oncol. 2019 Sep 11. pii: S0090-8258(19)31462.
    >> Share

  353. VERGOTE I, du Bois A, Floquet A, Rau J, et al
    Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2019 Sep 10. pii: S0090-8258(19)31476.
    >> Share

  354. GRONWALD J, Lubinski J, Huzarski T, Cybulski C, et al
    A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy.
    Gynecol Oncol. 2019 Sep 6. pii: S0090-8258(19)31486.
    >> Share

  355. HOLLIS RL, Stanley B, Iida Y, Thomson J, et al
    Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma.
    Gynecol Oncol. 2019 Sep 5. pii: S0090-8258(19)31487.
    >> Share

  356. JOHANSEN G, Dahm-Kahler P, Staf C, Floter Radestad A, et al
    Fertility-sparing surgery for treatment of non-epithelial ovarian cancer: Oncological and reproductive outcomes in a prospective nationwide population-based cohort study.
    Gynecol Oncol. 2019 Sep 4. pii: S0090-8258(19)31469.
    >> Share

  357. MAKII C, Ikeda Y, Oda K, Uehara Y, et al
    Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.
    Gynecol Oncol. 2019 Sep 4. pii: S0090-8258(19)31480.
    >> Share

  358. KAY AH, Urban RR, Gray HJ
    Intraperitoneal ports placed at the time of bowel resection for treatment of ovarian cancer: Complications and surgical outcomes.
    Gynecol Oncol. 2019 Sep 3. pii: S0090-8258(19)31472.
    >> Share

    August 2019
  359. TOZZI R, Traill Z, Campanile RG, Kilic Y, et al
    Diagnostic flow-chart to identify bowel involvement in patients with stage IIIC-IV ovarian cancer: Can laparoscopy improve the accuracy of CT scan?
    Gynecol Oncol. 2019 Aug 31. pii: S0090-8258(19)31477.
    >> Share

  360. ELZAKKERS JCJ, van der Aa MA, van Altena AM, de Hullu JA, et al
    Further insights into the role of tumour characteristics in survival of young women with epithelial ovarian cancer.
    Gynecol Oncol. 2019 Aug 30. pii: S0090-8258(19)31470.
    >> Share

  361. LONG ROCHE K, Gardner GJ
    State of the science: Evolving role of surgery for the treatment of ovarian cancer.
    Gynecol Oncol. 2019 Aug 28. pii: S0090-8258(19)31468.
    >> Share

  362. MATSUO K, Cripe JC, Kurnit KC, Kaneda M, et al
    Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer.
    Gynecol Oncol. 2019 Aug 16. pii: S0090-8258(19)31458.
    >> Share

  363. LIU YL, Zhou Q, Iasonos A, Emengo VN, et al
    Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer.
    Gynecol Oncol. 2019 Aug 14. pii: S0090-8258(19)31457.
    >> Share

  364. WEBBER K, Carolus E, Mileshkin L, Sommeijer D, et al
    OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors.
    Gynecol Oncol. 2019 Aug 12. pii: S0090-8258(19)31460.
    >> Share

  365. WADE KNS, Brady MF, Thai T, Wang Y, et al
    Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218.
    Gynecol Oncol. 2019 Aug 10. pii: S0090-8258(19)31409.
    >> Share

  366. KILTS TP, Glaser GE, Langstraat CL, Kumar A, et al
    Comparing risk stratification criteria for predicting lymphatic dissemination in endometrial cancer.
    Gynecol Oncol. 2019 Aug 10. pii: S0090-8258(19)31456.
    >> Share

  367. NARASIMHULU DM, Kumar A, Weaver AL, McGree ME, et al
    Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2019 Aug 8. pii: S0090-8258(19)31455.
    >> Share

  368. ZAMORANO AS, Hagemann AR, Morrison L, Lee JA, et al
    Pre-diagnosis body mass index, physical activity and ovarian cancer mortality.
    Gynecol Oncol. 2019 Aug 2. pii: S0090-8258(19)31449.
    >> Share

  369. SALYER C, Kobelka C, Barrie A, Weintraub MR, et al
    Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations.
    Gynecol Oncol. 2019;154:374-378.
    >> Share

    July 2019
  370. RANDALL LM, Wenham RM, Low PS, Dowdy SC, et al
    A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer.
    Gynecol Oncol. 2019 Jul 27. pii: S0090-8258(19)31396.
    >> Share

  371. RAMONDETTA LM, Hu W, Thaker PH, Urbauer DL, et al
    Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.
    Gynecol Oncol. 2019 Jul 25. pii: S0090-8258(19)31353.
    >> Share

  372. KATO K, Omi M, Fusegi A, Takeshima N, et al
    Modified posterior pelvic exenteration with pelvic side-wall resection requiring both intestinal and urinary reconstruction during surgery for ovarian cancer.
    Gynecol Oncol. 2019 Jul 24. pii: S0090-8258(19)31404.
    >> Share

  373. BARTELS HC, Rogers AC, McSharry V, McVey R, et al
    A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy.
    Gynecol Oncol. 2019 Jul 23. pii: S0090-8258(19)31397.
    >> Share

  374. CYBULSKA P, Paula ADC, Tseng J, Leitao MM Jr, et al
    Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
    Gynecol Oncol. 2019 Jul 21. pii: S0090-8258(19)31398.
    >> Share

  375. XIANG L, Ye S, Yang H
    Total pelvic peritonectomy for ovarian cancer with extensive peritoneal carcinomatosis in pelvic cavity.
    Gynecol Oncol. 2019 Jul 17. pii: S0090-8258(19)31352.
    >> Share

  376. HUBBARD AK, Poynter JN
    Global incidence comparisons and trends in ovarian germ cell tumors by geographic region in girls, adolescents and young women: 1988-2012.
    Gynecol Oncol. 2019 Jul 11. pii: S0090-8258(19)31348.
    >> Share

  377. MATSUO K, Huang Y, Zivanovic O, Shimada M, et al
    Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer.
    Gynecol Oncol. 2019 Jul 3. pii: S0090-8258(19)31337.
    >> Share

  378. KUMAR A, Sheedy S, Kim B, Suidan R, et al
    Models to predict outcomes after primary debulking surgery: Independent validation of models to predict suboptimal cytoreduction and gross residual disease.
    Gynecol Oncol. 2019;154:72-76.
    >> Share

    June 2019
  379. XIANG M, English DP, Kidd EA
    Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
    Gynecol Oncol. 2019 Jun 27. pii: S0090-8258(19)31336.
    >> Share

  380. KRANAWETTER M, Ataseven B, Grimm C, Schneider S, et al
    Low anterior resection syndrome (LARS) in patients with epithelial ovarian cancer after primary debulking surgery.
    Gynecol Oncol. 2019 Jun 21. pii: S0090-8258(19)31331.
    >> Share

  381. CANAZ E, Grabowski JP, Richter R, Braicu EI, et al
    Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Gynecol Oncol. 2019 Jun 20. pii: S0090-8258(19)31327.
    >> Share

  382. HENGEVELD EM, Zusterzeel PLM, Lajer H, Hogdall CK, et al
    The value of surgical staging in patients with apparent early stage epithelial ovarian carcinoma.
    Gynecol Oncol. 2019 Jun 20. pii: S0090-8258(19)31317.
    >> Share

  383. FUH KC, Java JJ, Chan JK, Kapp DS, et al
    Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.
    Gynecol Oncol. 2019 Jun 19. pii: S0090-8258(19)31257.
    >> Share

  384. TANG M, O'Connell RL, Amant F, Beale P, et al
    PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
    Gynecol Oncol. 2019 Jun 18. pii: S0090-8258(19)31322.
    >> Share

  385. MARIANI A, Wang C, Oberg AL, Riska SM, et al
    Genes associated with bowel metastases in ovarian cancer.
    Gynecol Oncol. 2019 Jun 14. pii: S0090-8258(19)31321.
    >> Share

  386. DOTTINO JA, He W, Sun CC, Zhao H, et al
    Centers for Medicare and Medicaid Services' Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores and gynecologic oncology surgical outcomes.
    Gynecol Oncol. 2019 Jun 14. pii: S0090-8258(19)31280.
    >> Share

  387. LIU JF, Gordon M, Veneris J, Braiteh F, et al
    Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
    Gynecol Oncol. 2019 Jun 13. pii: S0090-8258(19)31265.
    >> Share

  388. HORNER W, Peng K, Pleasant V, Brackmann M, et al
    Trends in surgical complexity and treatment modalities utilized in the management of ovarian cancer in an era of neoadjuvant chemotherapy.
    Gynecol Oncol. 2019 Jun 11. pii: S0090-8258(19)31267.
    >> Share

  389. BOITANO TKL, Barrington DA, Batra S, McGwin G Jr, et al
    Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
    Gynecol Oncol. 2019 Jun 10. pii: S0090-8258(19)31275.
    >> Share

  390. BERGAMINI A, Cormio G, Ferrandina G, Lorusso D, et al
    Conservative surgery in stage I adult type granulosa cells tumors of the ovary: Results from the MITO-9 study.
    Gynecol Oncol. 2019 Jun 10. pii: S0090-8258(19)31273.
    >> Share

  391. HARDING BN, Delaney JA, Urban RR, Weiss NS, et al
    Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer.
    Gynecol Oncol. 2019 Jun 6. pii: S0090-8258(19)31274.
    >> Share

  392. FRAZER JL, Hook CE, Addley HC, Jackson CR, et al
    Recurrent ovarian immature teratoma in a 12-year-old girl: Implications for management.
    Gynecol Oncol. 2019 Jun 5. pii: S0090-8258(19)31277.
    >> Share

  393. MOORE KN, Gunderson CC, Sabbatini P, McMeekin DS, et al
    A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2019 Jun 4. pii: S0090-8258(19)30496.
    >> Share

  394. WRIGHT JD, Chen L, Buskwofie A, Tergas AI, et al
    Regionalization of care for women with ovarian cancer.
    Gynecol Oncol. 2019 Jun 3. pii: S0090-8258(19)31269.
    >> Share

  395. SHERMAN-SAMIS M, Onallah H, Holth A, Reich R, et al
    SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma.
    Gynecol Oncol. 2019;153:651-660.
    >> Share

    May 2019
  396. GRETTE K, Long B, Finan MA, Rocconi RP, et al
    Intraperitoneal (IP) port cytology after completion of primary therapy for advanced stage ovarian cancer: A novel approach to a "second look".
    Gynecol Oncol. 2019 May 31. pii: S0090-8258(19)31236.
    >> Share

  397. NASIOUDIS D, Kahn R, Chapman-Davis E, Frey MK, et al
    Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma.
    Gynecol Oncol. 2019 May 31. pii: S0090-8258(19)31260.
    >> Share

  398. NASIOUDIS D, Haggerty AF, Giuntoli RL 2nd, Burger RA, et al
    Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma.
    Gynecol Oncol. 2019 May 30. pii: S0090-8258(19)31233.
    >> Share

  399. COHEN PA, Powell A, Bohm S, Gilks CB, et al
    Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
    Gynecol Oncol. 2019 May 19. pii: S0090-8258(19)31181.
    >> Share

  400. STASENKO M, Cybulska P, Feit N, Makker V, et al
    Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status.
    Gynecol Oncol. 2019 May 18. pii: S0090-8258(19)31229.
    >> Share

  401. CHAPMAN BV, Swanick CW, Ning MS, Allen PK, et al
    Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer.
    Gynecol Oncol. 2019 May 17. pii: S0090-8258(19)31227.
    >> Share

  402. GRANDI G, Perrone AM, Chiossi G, Friso S, et al
    Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study.
    Gynecol Oncol. 2019 May 16. pii: S0090-8258(19)31186.
    >> Share

  403. MARU Y, Tanaka N, Itami M, Hippo Y, et al
    Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
    Gynecol Oncol. 2019 May 14. pii: S0090-8258(19)31230.
    >> Share

  404. TOMAO F, Musacchio L, Di Mauro F, Boccia SM, et al
    Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
    Gynecol Oncol. 2019 May 9. pii: S0090-8258(19)30504.
    >> Share

  405. FILIPPOVA OT, Chi DS, Long Roche K, Sonoda Y, et al
    Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center.
    Gynecol Oncol. 2019 May 8. pii: S0090-8258(19)31185.
    >> Share

  406. VAN ARSDALE A, Miller DT, Kuo DY, Isani S, et al
    Association of obesity with survival in patients with endometrial cancer.
    Gynecol Oncol. 2019 May 3. pii: S0090-8258(19)30493.
    >> Share

  407. HOPPENOT C, Peters P, Cowan M, Moore ED, et al
    Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?
    Gynecol Oncol. 2019 May 2. pii: S0090-8258(19)31183.
    >> Share

  408. LEDERMANN JA
    Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?
    Gynecol Oncol. 2019;153:213-214.
    >> Share

  409. KRASNER CN, Castro C, Penson RT, Roche M, et al
    Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Mullerian origin.
    Gynecol Oncol. 2019;153:223-229.
    >> Share

    April 2019
  410. DANIELE G, Arenare L, Scambia G, Pisano C, et al
    Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.
    Gynecol Oncol. 2019 Apr 24. pii: S0090-8258(19)30507.
    >> Share

  411. FRANCIS SR, Ager BJ, Do OA, Huang YJ, et al
    Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy.
    Gynecol Oncol. 2019 Apr 24. pii: S0090-8258(19)31174.
    >> Share

  412. KENNARD JA, Stephens AJ, Ahmad S, Zhu X, et al
    Sentinel lymph nodes (SLN) in endometrial cancer: The relationship between primary tumor histology, SLN metastasis size, and non-sentinel node metastasis.
    Gynecol Oncol. 2019 Apr 23. pii: S0090-8258(19)31152.
    >> Share

  413. GORE M, Hackshaw A, Brady WE, Penson RT, et al
    An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
    Gynecol Oncol. 2019 Apr 17. pii: S0090-8258(19)30491.
    >> Share

  414. ALHILLI MM, Elson P, Rybicki L, Khorana AA, et al
    Delay in time to surgery and impact on survival in patients with endometrial cancer: A National Cancer Database Analysis.
    Gynecol Oncol. 2019 Apr 15. pii: S0090-8258(19)30437.
    >> Share

  415. MOORE RG, Blackman A, Miller MC, Robison K, et al
    Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?
    Gynecol Oncol. 2019 Apr 13. pii: S0090-8258(19)30501.
    >> Share

  416. HORSBOEL TA, Kjaer SK, Johansen C, Suppli NP, et al
    Increased risk for depression persists for years among women treated for gynecological cancers - a register-based cohort study with up to 19years of follow-up.
    Gynecol Oncol. 2019 Apr 8. pii: S0090-8258(19)30494.
    >> Share

  417. REIJNEN C, Kusters-Vandevelde HVN, Prinsen CF, Massuger LFAG, et al
    Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer.
    Gynecol Oncol. 2019 Apr 3. pii: S0090-8258(19)30270.
    >> Share

  418. LAGO V, Fotopoulou C, Chiantera V, Minig L, et al
    Risk factors for anastomotic leakage after colorectal resection in ovarian cancer surgery: A multi-centre study.
    Gynecol Oncol. 2019 Apr 2. pii: S0090-8258(19)30434.
    >> Share

  419. VAN BAAL JOAM, Van de Vijver KK, Algera MD, van der A MA, et al
    The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer.
    Gynecol Oncol. 2019 Apr 1. pii: S0090-8258(19)30492.
    >> Share

  420. PUECHL AM, Edwards J, Suri A, Nakayama J, et al
    The association between progesterone receptor expression and survival in women with adult granulosa cell tumors.
    Gynecol Oncol. 2019;153:74-79.
    >> Share

  421. MANNING-GEIST BL, Alimena S, Del Carmen MG, Goodman A, et al
    Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter?
    Gynecol Oncol. 2019;153:63-67.
    >> Share

    March 2019
  422. COSGROVE CM, Cohn DE, Rhoades J, Felix AS, et al
    The prognostic significance of aortic lymph node metastasis in endometrial cancer: Potential implications for selective aortic lymph node assessment.
    Gynecol Oncol. 2019 Mar 30. pii: S0090-8258(19)30486.
    >> Share

  423. DE ARRUDA FN, Oonk MHM, Mourits MJE, de Graeff P, et al
    Determinants of health-related quality of life in elderly ovarian cancer patients: The role of frailty and dependence.
    Gynecol Oncol. 2019 Mar 29. pii: S0090-8258(19)30485.
    >> Share

  424. LAAKSONEN MA, Arriaga ME, Canfell K, MacInnis RJ, et al
    The preventable burden of endometrial and ovarian cancers in Australia: A pooled cohort study.
    Gynecol Oncol. 2019 Mar 29. pii: S0090-8258(19)30275.
    >> Share

  425. SECORD AA, McCollum M, Davidson BA, Broadwater G, et al
    Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
    Gynecol Oncol. 2019 Mar 28. pii: S0090-8258(19)30441.
    >> Share

  426. GUO Y, Cui W, Pei Y, Xu D, et al
    Platelets promote invasion and induce epithelial to mesenchymal transition in ovarian cancer cells by TGF-beta signaling pathway.
    Gynecol Oncol. 2019 Mar 27. pii: S0090-8258(19)30136.
    >> Share

  427. DISILVESTRO PA
    Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years.
    Gynecol Oncol. 2019 Mar 22. pii: S0090-8258(19)30130.
    >> Share

  428. MORONEY MR, Davies KD, Wilberger AC, Sheeder J, et al
    Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
    Gynecol Oncol. 2019 Mar 22. pii: S0090-8258(19)30273.
    >> Share

  429. MACHIDA H, Matsuo K, Yamagami W, Ebina Y, et al
    Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO-JSOG joint study.
    Gynecol Oncol. 2019 Mar 21. pii: S0090-8258(19)30436.
    >> Share

  430. HEILMANN T, Pfisterer J, Hempel AM, Sass S, et al
    Early treatment modifications improve chemotherapy adherence in ovarian cancer patients >/=70years.
    Gynecol Oncol. 2019 Mar 21. pii: S0090-8258(19)30125.
    >> Share

  431. LAWRENSON K, Song F, Hazelett DJ, Kar SP, et al
    Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women.
    Gynecol Oncol. 2019 Mar 19. pii: S0090-8258(19)30133.
    >> Share

  432. HUANG M, Kamath P, Schlumbrecht M, Miao F, et al
    Identifying disparities in germline and somatic testing for ovarian cancer.
    Gynecol Oncol. 2019 Mar 16. pii: S0090-8258(19)30155.
    >> Share

  433. RATNER E, Bala M, Louie-Gao M, Aydin E, et al
    Increased risk of brain metastases in ovarian cancer patients with BRCA mutations.
    Gynecol Oncol. 2019 Mar 12. pii: S0090-8258(19)30152.
    >> Share

  434. LAVIE O, Chetrit A, Novikov I, Sadetzki S, et al
    Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
    Gynecol Oncol. 2019 Mar 11. pii: S0090-8258(19)30132.
    >> Share

  435. MURAKAMI R, Matsumura N, Michimae H, Tanabe H, et al
    The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology G
    Gynecol Oncol. 2019 Mar 7. pii: S0090-8258(19)30120.
    >> Share

  436. SON JH, Kim J, Shim J, Kong TW, et al
    Comparison of posterior rectal dissection techniques during rectosigmoid colon resection as part of cytoreductive surgery in patients with epithelial ovarian cancer: Close rectal dissection versus total mesorectal excision.
    Gynecol Oncol. 2019 Mar 4. pii: S0090-8258(19)30139.
    >> Share

  437. MERT I, Kumar A, Torres D, Huang Y, et al
    Should mucosal bowel invasion in ovarian cancer be assigned to FIGO stage IV disease?
    Gynecol Oncol. 2019 Mar 2. pii: S0090-8258(19)30128.
    >> Share

  438. MEYER LA, Shi Q, Lasala J, Iniesta MD, et al
    Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery.
    Gynecol Oncol. 2019;152:501-508.
    >> Share

  439. KWON JS, Tinker AV, Hanley GE, Pansegrau G, et al
    BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
    Gynecol Oncol. 2019;152:459-464.
    >> Share

  440. TAYLOR JS, Zhang N, Rajan SS, Chavez-MacGregor M, et al
    How we use hospice: Hospice enrollment patterns and costs in elderly ovarian cancer patients.
    Gynecol Oncol. 2019;152:452-458.
    >> Share

  441. FOOTE JR, Secord AA, Liang MI, Ehrisman JA, et al
    Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2019;152:445-451.
    >> Share

  442. FELDER M, Kapur A, Rakhmilevich AL, Qu X, et al
    MUC16 suppresses human and murine innate immune responses.
    Gynecol Oncol. 2019;152:618-628.
    >> Share

    February 2019
  443. TIMMERMANS M, van der Hel O, Sonke GS, Van de Vijver KK, et al
    The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review.
    Gynecol Oncol. 2019 Feb 27. pii: S0090-8258(19)30129.
    >> Share

  444. MORSE CB, Toukatly MN, Kilgore MR, Agnew KJ, et al
    Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.
    Gynecol Oncol. 2019 Feb 22. pii: S0090-8258(19)30121.
    >> Share

  445. MCGUIRE S, Kara B, Hart PC, Montag A, et al
    Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis.
    Gynecol Oncol. 2019 Feb 20. pii: S0090-8258(19)30059.
    >> Share

  446. MATSUO K, Machida H, Mandelbaum RS, Grubbs BH, et al
    Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.
    Gynecol Oncol. 2019 Feb 20. pii: S0090-8258(19)30106.
    >> Share

  447. MESQUITA KA, Alabdullah M, Griffin M, Toss MS, et al
    ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
    Gynecol Oncol. 2019 Feb 20. pii: S0090-8258(19)30124.
    >> Share

  448. VAN WALREE IC, Hamaker ME, van de Poll-Franse LV, Vos MC, et al
    Older ovarian cancer survivors report lower long-term health-related quality of life than younger survivors: A study from the population-based profiles registry.
    Gynecol Oncol. 2019 Feb 13. pii: S0090-8258(19)30104.
    >> Share

  449. NAUMANN RW, Coleman RL, Brown J, Moore KN, et al
    Phase III trials in ovarian cancer: The evolving landscape of front line therapy.
    Gynecol Oncol. 2019 Feb 12. pii: S0090-8258(19)30113.
    >> Share

  450. LIANG J, Wolsiefer K, Zestcott CA, Chase D, et al
    Implicit bias toward cervical cancer: Provider and training differences.
    Gynecol Oncol. 2019 Feb 7. pii: S0090-8258(19)30055.
    >> Share

  451. SUSZYNSKA M, Klonowska K, Jasinska AJ, Kozlowski P, et al
    Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.
    Gynecol Oncol. 2019 Feb 4. pii: S0090-8258(19)30069.
    >> Share

  452. LIM SL, Havrilesky LJ, Habib AS, Secord AA, et al
    Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy.
    Gynecol Oncol. 2019 Feb 1. pii: S0090-8258(19)30067.
    >> Share

  453. VOGEL RI, Niendorf K, Petzel S, Lee H, et al
    A patient-centered mobile health application to motivate use of genetic counseling among women with ovarian cancer: A pilot randomized controlled trial.
    Gynecol Oncol. 2019 Feb 1. pii: S0090-8258(19)30062.
    >> Share

  454. ORSULIC S, Karlan BY
    Can molecular subtyping be used to triage women with advanced ovarian cancer to Primary Debulking Surgery or Neoadjuvant Chemotherapy?
    Gynecol Oncol. 2019;152:221-222.
    >> Share

  455. XIN W, Hua K, Ding J
    The way to display the chylous tubes and to prevent chylous leakage in laparoscopic para-aortic lymphadenectomy.
    Gynecol Oncol. 2019;152:434-435.
    >> Share

  456. SMITH JA, Le T, Martin GA, Gaikwad A, et al
    Identifying the need to refine the potential patient risk factors for niraparib-induced thrombocytopenia.
    Gynecol Oncol. 2019;152:265-269.
    >> Share

  457. FLEM KARLSEN K, McFadden E, Florenes VA, Davidson B, et al
    Soluble AXL is ubiquitously present in malignant serous effusions.
    Gynecol Oncol. 2019;152:408-415.
    >> Share

    January 2019
  458. HOSKINS P, Eccleston A, Hurry M, Dyer M, et al
    Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model.
    Gynecol Oncol. 2019 Jan 28. pii: S0090-8258(19)30061.
    >> Share

  459. MODUGNO F, Goughnour SL, Wallack D, Edwards RP, et al
    Breastfeeding factors and risk of epithelial ovarian cancer.
    Gynecol Oncol. 2019 Jan 25. pii: S0090-8258(19)30060.
    >> Share

  460. CHOI HJ, Heo JH, Park JY, Jeong JY, et al
    A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Gynecol Oncol. 2019 Jan 25. pii: S0090-8258(19)30045.
    >> Share

  461. HURLEY RM, Wahner Hendrickson AE, Visscher DW, Ansell P, et al
    53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
    Gynecol Oncol. 2019 Jan 24. pii: S0090-8258(19)30058.
    >> Share

  462. UPPENDAHL LD, Felices M, Bendzick L, Ryan C, et al
    Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.
    Gynecol Oncol. 2019 Jan 15. pii: S0090-8258(19)30039.
    >> Share

  463. DING J, Cheng XY, Liu S, Ji HY, et al
    Apatinib exerts anti-tumour effects on ovarian cancer cells.
    Gynecol Oncol. 2019 Jan 14. pii: S0090-8258(19)30043.
    >> Share

  464. BREGAR A, Mojtahed A, Kilcoyne A, Kurra V, et al
    CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy.
    Gynecol Oncol. 2019 Jan 11. pii: S0090-8258(18)31476.
    >> Share

  465. MCCUAIG JM, Tone AA, Maganti M, Romagnuolo T, et al
    Modified panel-based genetic counseling for ovarian cancer susceptibility: A randomized non-inferiority study.
    Gynecol Oncol. 2019 Jan 10. pii: S0090-8258(18)31541.
    >> Share

  466. FABBRO M, Moore KN, Dorum A, Tinker AV, et al
    Efficacy and safety of niraparib as maintenance treatment in older patients (>/=70years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
    Gynecol Oncol. 2019 Jan 9. pii: S0090-8258(18)31473.
    >> Share

  467. JERZAK KJ, Duska L, MacKay HJ
    Endocrine therapy in endometrial cancer: An old dog with new tricks.
    Gynecol Oncol. 2019 Jan 4. pii: S0090-8258(18)31518.
    >> Share

  468. YAO T, DeJong SR, McGree ME, Weaver AL, et al
    Frailty in ovarian cancer identified the need for increased postoperative care requirements following cytoreductive surgery.
    Gynecol Oncol. 2019 Jan 3. pii: S0090-8258(18)31539.
    >> Share

  469. SULLIVAN MW, Camacho FT, Mills AM, Modesitt SC, et al
    Missing information in statewide and national cancer databases: Correlation with health risk factors, geographic disparities, and outcomes.
    Gynecol Oncol. 2019;152:119-126.
    >> Share

    December 2018
  470. MATULONIS UA, Sill MW, Makker V, Mutch DG, et al
    A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 Dec 23. pii: S0090-8258(18)31460.
    >> Share

  471. RAUH-HAIN JA, Hidrue MK, Gaccione P, Melamed A, et al
    Variation in resource utilization associated with the surgical management of ovarian cancer.
    Gynecol Oncol. 2018 Dec 19. pii: S0090-8258(18)31513.
    >> Share

  472. MYSONA D, Pyrzak A, Purohit S, Zhi W, et al
    A combined score of clinical factors and serum proteins can predict time to recurrence in high grade serous ovarian cancer.
    Gynecol Oncol. 2018 Dec 18. pii: S0090-8258(18)31515.
    >> Share

  473. CEPPI L, Galli F, Lamanna M, Magni S, et al
    Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms.
    Gynecol Oncol. 2018 Dec 18. pii: S0090-8258(18)31452.
    >> Share

  474. NIE D, Gong H, Mao X, Li Z, et al
    Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: A retrospective study.
    Gynecol Oncol. 2018 Dec 14. pii: S0090-8258(18)31454.
    >> Share

  475. DAVIDSON BA, Broadwater G, Crim A, Boccacio R, et al
    Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy.
    Gynecol Oncol. 2018 Dec 14. pii: S0090-8258(18)31475.
    >> Share

  476. ANGELES MA, Martinez-Gomez C, Martinez A, Ferron G, et al
    En bloc pelvic resection for ovarian carcinomatosis: Hudson procedure in 10 steps.
    Gynecol Oncol. 2018 Dec 14. pii: S0090-8258(18)31471.
    >> Share

  477. RODRIGUEZ-FREIXINOS V, Farinas-Madrid L, Gil-Martin M, Barretina-Ginesta P, et al
    Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
    Gynecol Oncol. 2018 Dec 12. pii: S0090-8258(18)31456.
    >> Share

  478. NORQUIST BM
    Challenges in the identification of inherited risk of ovarian cancer: where should we go from here?
    Gynecol Oncol. 2018 Dec 8. pii: S0090-8258(18)31459.
    >> Share

  479. BEDNAR EM, Sun CC, Camacho B, Terrell J, et al
    Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic.
    Gynecol Oncol. 2018 Dec 8. pii: S0090-8258(18)31457.
    >> Share

  480. VARGA A, Piha-Paul S, Ott PA, Mehnert JM, et al
    Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
    Gynecol Oncol. 2018 Dec 3. pii: S0090-8258(18)31418.
    >> Share

    November 2018
  481. TORRES D, Kumar A, Bakkum-Gamez JN, Weaver AL, et al
    Mesenchymal molecular subtype is an independent predictor of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.
    Gynecol Oncol. 2018 Nov 28. pii: S0090-8258(18)31420.
    >> Share

  482. HAY CM, Donovan HS, Campbell GB, Taylor SE, et al
    Chemotherapy in older adult gynecologic oncology patients: Can a phenotypic frailty score predict tolerance?
    Gynecol Oncol. 2018 Nov 28. pii: S0090-8258(18)31451.
    >> Share

  483. STANLEY B, Hollis RL, Nunes H, Towler JD, et al
    Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors.
    Gynecol Oncol. 2018 Nov 27. pii: S0090-8258(18)31450.
    >> Share

  484. SUBRAMANIAM A, Einerson BD, Blanchard CT, Erickson BK, et al
    The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction.
    Gynecol Oncol. 2018 Nov 23. pii: S0090-8258(18)31405.
    >> Share

  485. WAGNER BE, Langstraat CL, McGree ME, Weaver AL, et al
    Beyond prophylaxis: Extended risk of venous thromboembolism following primary debulking surgery for ovarian cancer.
    Gynecol Oncol. 2018 Nov 21. pii: S0090-8258(18)31422.
    >> Share

  486. JAVELLANA M, Hoppenot C, Lengyel E
    The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
    Gynecol Oncol. 2018 Nov 21. pii: S0090-8258(18)31404.
    >> Share

  487. BOLAND JL, Zhou Q, Martin M, Callahan MK, et al
    Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.
    Gynecol Oncol. 2018 Nov 20. pii: S0090-8258(18)31445.
    >> Share

  488. HEITZ F, Harter P, Avall-Lundqvist E, Reuss A, et al
    Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.
    Gynecol Oncol. 2018 Nov 19. pii: S0090-8258(18)31406.
    >> Share

  489. PRADER S, Vollmar N, du Bois A, Heitz F, et al
    Pattern and impact of metastatic cardiophrenic lymph nodes in advanced epithelial ovarian cancer.
    Gynecol Oncol. 2018 Nov 18. pii: S0090-8258(18)31363.
    >> Share

  490. GONZALEZ MARTIN A, Oza AM, Embleton AC, Pfisterer J, et al
    Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.
    Gynecol Oncol. 2018 Nov 15. pii: S0090-8258(18)31166.
    >> Share

  491. ZHANG Q, Wang C, Cliby WA
    Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.
    Gynecol Oncol. 2018 Nov 15. pii: S0090-8258(18)31415.
    >> Share

  492. KOTOULA V, Lakis S, Tikas I, Giannoulatou E, et al
    Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients.
    Gynecol Oncol. 2018 Nov 14. pii: S0090-8258(18)31417.
    >> Share

  493. ROMEO C, Joly F, Ray-Coquard I, El Kouri C, et al
    Non-pegylated liposomal doxorubicin (NPLD, Myocet(R))+carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.
    Gynecol Oncol. 2018 Nov 14. pii: S0090-8258(18)31358.
    >> Share

  494. ZHONG Q, Hu Z, Li Q, Yi T, et al
    Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
    Gynecol Oncol. 2018 Nov 7. pii: S0090-8258(18)31310.
    >> Share

  495. TURASHVILI G, Gomez-Hidalgo NR, Flynn J, Gonen M, et al
    Risk-based stratification of carcinomas concurrently involving the endometrium and ovary.
    Gynecol Oncol. 2018 Nov 6. pii: S0090-8258(18)31315.
    >> Share

  496. LEE JY, Park JY, Park SY, Lee JW, et al
    Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
    Gynecol Oncol. 2018 Nov 5. pii: S0090-8258(18)31314.
    >> Share

  497. MULLEN MM, Kuroki LM, Thaker PH
    Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review.
    Gynecol Oncol. 2018 Nov 5. pii: S0090-8258(18)31306.
    >> Share

  498. SELLA T, Stone RM
    The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: Understanding the baseline incidence.
    Gynecol Oncol. 2018;151:187-189.
    >> Share

    October 2018
  499. WANG Y, Jiang J, He L, Gong G, et al
    Effect of lamin-A expression on migration and nuclear stability of ovarian cancer cells.
    Gynecol Oncol. 2018 Oct 29. pii: S0090-8258(18)31313.
    >> Share

  500. HANSEN JM, Sood AK, Coleman RL, Westin SN, et al
    Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer.
    Gynecol Oncol. 2018 Oct 23. pii: S0090-8258(18)31299.
    >> Share

  501. HINCHCLIFF E, Hong D, Le H, Chisholm G, et al
    Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials.
    Gynecol Oncol. 2018 Oct 23. pii: S0090-8258(18)31287.
    >> Share

  502. OLAWAIYE AB, Java JJ, Krivak TC, Friedlander M, et al
    Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23].
    Gynecol Oncol. 2018 Oct 22. pii: S0090-8258(18)31303.
    >> Share

  503. TA RM, Hecht JL, Lin DI
    Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors.
    Gynecol Oncol. 2018 Oct 16. pii: S0090-8258(18)31291.
    >> Share

  504. TANNER EJ, Filippova OT, Gardner GJ, Long Roche KC, et al
    A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2018 Oct 15. pii: S0090-8258(18)31285.
    >> Share

  505. CARTER NJ, Marshall ML, Susswein LR, Zorn KK, et al
    Germline pathogenic variants identified in women with ovarian tumors.
    Gynecol Oncol. 2018 Oct 12. pii: S0090-8258(18)31249.
    >> Share

  506. KIM HS, Kim JY, Lee YJ, Kim SH, et al
    Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
    Gynecol Oncol. 2018 Oct 9. pii: S0090-8258(18)31153.
    >> Share

  507. NAUMANN RW, Morris JC, Tait DL, Higgins RV, et al
    Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer.
    Gynecol Oncol. 2018 Oct 8. pii: S0090-8258(18)31282.
    >> Share

  508. MONK BJ, Kauderer JT, Moxley KM, Bonebrake AJ, et al
    A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2018 Oct 8. pii: S0090-8258(18)31281.
    >> Share

  509. BELUR NAGARAJ A, Joseph P, Kovalenko O, Wang Q, et al
    Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer.
    Gynecol Oncol. 2018 Oct 6. pii: S0090-8258(18)31238.
    >> Share

  510. WANG J, Dean DC, Hornicek FJ, Shi H, et al
    RNA sequencing (RNA-Seq) and its application in ovarian cancer.
    Gynecol Oncol. 2018 Oct 5. pii: S0090-8258(18)31283.
    >> Share

  511. WANG W, Zou W, Liu JR
    Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy.
    Gynecol Oncol. 2018;151:1-3.
    >> Share

  512. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Successful retroperitoneal lymphadenectomy for double inferior vena cava with preoperative assessment using contrast-enhanced and three-dimensional computed tomography.
    Gynecol Oncol. 2018;151:180-181.
    >> Share

    September 2018
  513. ELNAGGAR AC, Hade EM, O'Malley DM, Liang MI, et al
    Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.
    Gynecol Oncol. 2018 Sep 30. pii: S0090-8258(18)31233.
    >> Share

  514. NASSER S, Lathouras K, Nixon K, Campbell J, et al
    Impact of right upper quadrant cytoreductive techniques with extensive liver mobilization on postoperative hepatic function and risk of liver failure in patients with advanced ovarian cancer.
    Gynecol Oncol. 2018 Sep 29. pii: S0090-8258(18)31247.
    >> Share

  515. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Left cardiophrenic lymph node resection for advanced ovarian cancer with adhesion to the thoracic cavity.
    Gynecol Oncol. 2018 Sep 27. pii: S0090-8258(18)31241.
    >> Share

  516. SHENOLIKAR R, Durden E, Meyer N, Lenhart G, et al
    Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
    Gynecol Oncol. 2018 Sep 26. pii: S0090-8258(18)31176.
    >> Share

  517. NIEMI RJ, Roine AN, Eraviita E, Kumpulainen PS, et al
    FAIMS analysis of urine gaseous headspace is capable of differentiating ovarian cancer.
    Gynecol Oncol. 2018 Sep 23. pii: S0090-8258(18)31235.
    >> Share

  518. TAYLOR JS, He W, Harrison R, Zhao H, et al
    Disparities in treatment and survival among elderly ovarian cancer patients.
    Gynecol Oncol. 2018 Sep 22. pii: S0090-8258(18)31171.
    >> Share

  519. ZIVANOVIC O, Chi DS, Filippova O, Randall LM, et al
    It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer.
    Gynecol Oncol. 2018 Sep 21. pii: S0090-8258(18)31218.
    >> Share

  520. HUA W, Zhao Y, Jin X, Yu D, et al
    METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition.
    Gynecol Oncol. 2018 Sep 21. pii: S0090-8258(18)31234.
    >> Share

  521. WANG D, Cao D, Jia C, Huang H, et al
    Analysis of oncologic and reproductive outcomes after fertility-sparing surgery in apparent stage I adult ovarian granulosa cell tumors.
    Gynecol Oncol. 2018 Sep 12. pii: S0090-8258(18)31214.
    >> Share

  522. ODA K, Hamanishi J, Matsuo K, Hasegawa K, et al
    Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
    Gynecol Oncol. 2018 Sep 11. pii: S0090-8258(18)31174.
    >> Share

  523. AZIZ D, Etemadmoghadam D, Caldon CE, Au-Yeung G, et al
    19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
    Gynecol Oncol. 2018 Sep 9. pii: S0090-8258(18)31169.
    >> Share

  524. ZHAO H, Yu H, Zheng J, Ning N, et al
    Lowly-expressed lncRNA GAS5 facilitates progression of ovarian cancer through targeting miR-196-5p and thereby regulating HOXA5.
    Gynecol Oncol. 2018 Sep 7. pii: S0090-8258(18)31162.
    >> Share

  525. CONNOR JP, O'Shea A, McCool K, Sampene E, et al
    Peri-operative allogeneic blood transfusion is associated with poor overall survival in advanced epithelial ovarian Cancer; potential impact of patient blood management on Cancer outcomes.
    Gynecol Oncol. 2018 Sep 7. pii: S0090-8258(18)31170.
    >> Share

  526. RAJKUMAR S, Polson A, Nath R, Lane G, et al
    Prognostic implications of histological tumor regression (Bohm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
    Gynecol Oncol. 2018 Sep 6. pii: S0090-8258(18)31172.
    >> Share

  527. SCURRY J, van Zyl B, Gulliver D, Otton G, et al
    Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer.
    Gynecol Oncol. 2018 Sep 4. pii: S0090-8258(18)31160.
    >> Share

  528. MILLS KA, Roach ST, Quinn JM, Guo L, et al
    SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth.
    Gynecol Oncol. 2018 Sep 3. pii: S0090-8258(18)31097.
    >> Share

  529. TSENG JH, Cowan RA, Afonso AM, Zhou Q, et al
    Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer.
    Gynecol Oncol. 2018 Sep 2. pii: S0090-8258(18)31154.
    >> Share

    August 2018
  530. TEW WP, Sill MW, Walker JL, Secord AA, et al
    Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2018 Aug 31. pii: S0090-8258(18)31157.
    >> Share

  531. SCHLAPPE BA, Weaver AL, Ducie JA, Eriksson AGZ, et al
    Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy.
    Gynecol Oncol. 2018 Aug 31. pii: S0090-8258(18)31152.
    >> Share

  532. VAN NIEUWENHUYSEN E, Busschaert P, Neven P, Han SN, et al
    The genetic landscape of 87 ovarian germ cell tumors.
    Gynecol Oncol. 2018 Aug 28. pii: S0090-8258(18)31130.
    >> Share

  533. DIOUN S, Jorgensen JR, Miller EM, Tymon-Rosario J, et al
    Unplanned hospitalizations in a racially and ethnically diverse population of women receiving chemotherapy for epithelial ovarian cancer.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31150.
    >> Share

  534. CHANG JS, Kim SW, Kim YJ, Kim JY, et al
    Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31129.
    >> Share

  535. LYCKE M, Kristjansdottir B, Sundfeldt K
    A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31155.
    >> Share

  536. NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
    Resection of a metastatic bulky subphrenic tumor for the treatment of advanced ovarian cancer using liver mobilization and the Pringle maneuver.
    Gynecol Oncol. 2018 Aug 20. pii: S0090-8258(18)31134.
    >> Share

  537. OLAWAIYE AB, Java JJ, Krivak TC, Friedlander M, et al
    Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 Aug 19. pii: S0090-8258(18)31085.
    >> Share

  538. TSENG JH, Cowan RA, Zhou Q, Iasonos A, et al
    Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?
    Gynecol Oncol. 2018 Aug 17. pii: S0090-8258(18)31131.
    >> Share

  539. SON JH, Lee JH, Jung JA, Kong TW, et al
    Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery.
    Gynecol Oncol. 2018 Aug 16. pii: S0090-8258(18)31098.
    >> Share

  540. PERES LC, Cushing-Haugen KL, Anglesio M, Wicklund K, et al
    Histotype classification of ovarian carcinoma: A comparison of approaches.
    Gynecol Oncol. 2018 Aug 15. pii: S0090-8258(18)31133.
    >> Share

  541. CONNOR EV, Newlin EM, Jelovsek JE, AlHilli MM, et al
    Predicting non-home discharge in epithelial ovarian cancer patients: External validation of a predictive model.
    Gynecol Oncol. 2018 Aug 11. pii: S0090-8258(18)31128.
    >> Share

  542. WINTERHOFF BJ, Maile M, Mitra AK, Sebe A, et al
    Corrigendum to "Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells" [Gyncol. Oncol. 144 (2017) 598-606].
    Gynecol Oncol. 2018 Aug 7. pii: S0090-8258(18)31079.
    >> Share

  543. MOORE KN, O'Malley DM, Vergote I, Martin LP, et al
    Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2018 Aug 6. pii: S0090-8258(18)31081.
    >> Share

  544. MALLEN A, Soong TR, Townsend MK, Wenham RM, et al
    Surgical prevention strategies in ovarian cancer.
    Gynecol Oncol. 2018 Aug 4. pii: S0090-8258(18)31094.
    >> Share

  545. LI A, Xie R, Zhi Q, Deng Y, et al
    BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
    Gynecol Oncol. 2018 Aug 2. pii: S0090-8258(18)31088.
    >> Share

  546. PINTO MP, Balmaceda C, Bravo ML, Kato S, et al
    Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
    Gynecol Oncol. 2018 Aug 2. pii: S0090-8258(18)31089.
    >> Share

  547. LEVINE DA
    The limits of aggressive surgical cytoreduction.
    Gynecol Oncol. 2018;150:205-206.
    >> Share

  548. MANNING-GEIST BL, Hicks-Courant K, Gockley AA, Clark RM, et al
    Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?
    Gynecol Oncol. 2018;150:233-238.
    >> Share

  549. SHAH R, Xia C, Krailo M, Amatruda JF, et al
    Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?
    Gynecol Oncol. 2018;150:253-260.
    >> Share

    July 2018
  550. BEHBAKHT K, Cohn DE, Straughn JM Jr
    Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer.
    Gynecol Oncol. 2018 Jul 30. pii: S0090-8258(18)31083.
    >> Share

  551. SONG M, Kumaran MN, Gounder M, Gibbon DG, et al
    Phase I trial of selenium plus chemotherapy in gynecologic cancers.
    Gynecol Oncol. 2018 Jul 29. pii: S0090-8258(18)31014.
    >> Share

  552. VERGOTE I, von Moos R, Manso L, Van Nieuwenhuysen E, et al
    Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.
    Gynecol Oncol. 2018 Jul 27. pii: S0090-8258(18)31082.
    >> Share

  553. MEAGHER NS, Schuster K, Voss A, Budden T, et al
    Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
    Gynecol Oncol. 2018 Jul 24. pii: S0090-8258(18)31077.
    >> Share

  554. NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
    Metastatic cardiophrenic lymph node resection following full-thickness resection of right diaphragm for advanced ovarian carcinoma.
    Gynecol Oncol. 2018 Jul 19. pii: S0090-8258(18)31067.
    >> Share

  555. BI Y, Verginadis II, Dey S, Lin L, et al
    Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
    Gynecol Oncol. 2018 Jul 16. pii: S0090-8258(18)31015.
    >> Share

  556. TIMMERMANS M, van der Aa MA, Lalisang RI, Witteveen PO, et al
    Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
    Gynecol Oncol. 2018 Jul 9. pii: S0090-8258(18)31017.
    >> Share

  557. DENG K, Yang C, Tan Q, Song W, et al
    Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients.
    Gynecol Oncol. 2018 Jul 9. pii: S0090-8258(18)31004.
    >> Share

  558. BARNARD ME, Pyden A, Rice MS, Linares M, et al
    Inter-pathologist and pathology report agreement for ovarian tumor characteristics in the Nurses' Health Studies.
    Gynecol Oncol. 2018 Jul 9. pii: S0090-8258(18)31016.
    >> Share

  559. BURGER RA, Deng W, Makker V, Collins Y, et al
    Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 Jul 2. pii: S0090-8258(18)30999.
    >> Share

  560. SECORD AA, Previs RA, Nixon AB
    Cabozantinib in ovarian clear cell cancers: UnMET expectations.
    Gynecol Oncol. 2018;150:1-2.
    >> Share

  561. CIUCCI A, Ferrandina G, Mascilini F, Filippetti F, et al
    Estrogen receptor beta: Potential target for therapy in adult granulosa cell tumors?
    Gynecol Oncol. 2018;150:158-165.
    >> Share

    June 2018
  562. MEYER LA, He W, Sun CC, Zhao H, et al
    Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness.
    Gynecol Oncol. 2018 Jun 29. pii: S0090-8258(18)31002.
    >> Share

  563. ZHANG XS, Zhang YM, Li B, Fan B, et al
    Risk reduction of endometrial and ovarian cancer after bisphosphonates use: A meta-analysis.
    Gynecol Oncol. 2018 Jun 27. pii: S0090-8258(18)30988.
    >> Share

  564. VERDOODT F, Dehlendorff C, Friis S, Kjaer SK, et al
    Non-aspirin NSAID use and ovarian cancer mortality.
    Gynecol Oncol. 2018 Jun 27. pii: S0090-8258(18)31000.
    >> Share

  565. GOCKLEY AA, Kolin DL, Awtrey CS, Lindeman NI, et al
    Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.
    Gynecol Oncol. 2018 Jun 21. pii: S0090-8258(18)30937.
    >> Share

  566. ROSS MS, Burriss ME, Winger DG, Edwards RP, et al
    Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30984.
    >> Share

  567. CLARK RM, Rice LW, Del Carmen MG
    Thirty-day unplanned hospital readmission in ovarian cancer patients undergoing primary or interval cytoreductive surgery: systematic literature review.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30985.
    >> Share

  568. URBAN RR, Pappas TC, Bullock RG, Munroe DG, et al
    Combined symptom index and second-generation multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30946.
    >> Share

  569. TORRES D, Wang C, Kumar A, Bakkum-Gamez JN, et al
    Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability.
    Gynecol Oncol. 2018 Jun 17. pii: S0090-8258(18)30944.
    >> Share

  570. LI N, Zhan X, Zhan X
    The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes.
    Gynecol Oncol. 2018 Jun 16. pii: S0090-8258(18)30989.
    >> Share

  571. CHAN JK, Brady W, Monk BJ, Brown J, et al
    A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
    Gynecol Oncol. 2018 Jun 16. pii: S0090-8258(18)30941.
    >> Share

  572. GRAETZ I, Anderson JN, McKillop CN, Stepanski EJ, et al
    Use of a web-based app to improve postoperative outcomes for patients receiving gynecological oncology care: A randomized controlled feasibility trial.
    Gynecol Oncol. 2018 Jun 11. pii: S0090-8258(18)30983.
    >> Share

  573. WOOLDERINK JM, De Bock GH, de Hullu JA, Hollema H, et al
    Characteristics of Lynch syndrome associated ovarian cancer.
    Gynecol Oncol. 2018 Jun 4. pii: S0090-8258(18)30240.
    >> Share

    May 2018
  574. LINDEMANN K, Gao B, Mapagu C, Fereday S, et al
    Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
    Gynecol Oncol. 2018 May 25. pii: S0090-8258(18)30907.
    >> Share

  575. GIANNOPOULOU L, Mastoraki S, Buderath P, Strati A, et al
    ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer.
    Gynecol Oncol. 2018 May 25. pii: S0090-8258(18)30922.
    >> Share

  576. KOTSOPOULOS J, Gronwald J, Karlan B, Rosen B, et al
    Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2018 May 21. pii: S0090-8258(18)30898.
    >> Share

  577. MUELLER JJ, Schlappe BA, Kumar R, Olvera N, et al
    Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses.
    Gynecol Oncol. 2018 May 21. pii: S0090-8258(18)30895.
    >> Share

  578. VON GRUENIGEN VE, Huang HQ, Cella D, Zevon M, et al
    Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 May 17. pii: S0090-8258(18)30904.
    >> Share

  579. O'SHEA A, McCool K, Harrison R, Sampene E, et al
    Neoadjuvant chemotherapy is associated with more anemia and perioperative blood transfusions than primary debulking surgery in women with advanced stage ovarian cancer.
    Gynecol Oncol. 2018 May 15. pii: S0090-8258(18)30901.
    >> Share

  580. RUSCITO I, Darb-Esfahani S, Kulbe H, Bellati F, et al
    The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2018 May 10. pii: S0090-8258(18)30892.
    >> Share

  581. BAERT T, Van Camp J, Vanbrabant L, Busschaert P, et al
    Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients.
    Gynecol Oncol. 2018 May 8. pii: S0090-8258(18)30891.
    >> Share

  582. NASIOUDIS D, Mastroyannis SA, Albright BB, Haggerty AF, et al
    Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes.
    Gynecol Oncol. 2018 May 8. pii: S0090-8258(18)30845.
    >> Share

  583. TEMPFER CB, Giger-Pabst U, Seebacher V, Petersen M, et al
    A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis.
    Gynecol Oncol. 2018 May 6. pii: S0090-8258(18)30851.
    >> Share

  584. KONSTANTINOPOULOS PA, Brady WE, Farley J, Armstrong A, et al
    Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).
    Gynecol Oncol. 2018 May 5. pii: S0090-8258(18)30850.
    >> Share

  585. NEBGEN DR, Hurteau J, Holman LL, Bradford A, et al
    Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
    Gynecol Oncol. 2018 May 4. pii: S0090-8258(18)30842.
    >> Share

    April 2018
  586. NISKAKOSKI A, Pasanen A, Porkka N, Eldfors S, et al
    Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas.
    Gynecol Oncol. 2018 Apr 28. pii: S0090-8258(18)30844.
    >> Share

  587. WANG J, Garbutt C, Ma H, Gao P, et al
    Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.
    Gynecol Oncol. 2018 Apr 23. pii: S0090-8258(18)30835.
    >> Share

  588. CHAPEL DB, Yamada SD, Cowan M, Lastra RR, et al
    Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
    Gynecol Oncol. 2018 Apr 13. pii: S0090-8258(18)30282.
    >> Share

  589. UYAR D, Neary J, Monroe A, Nugent M, et al
    Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer.
    Gynecol Oncol. 2018 Apr 10. pii: S0090-8258(18)30239.
    >> Share

  590. LIU J, Nicum S, Reichardt P, Croitoru K, et al
    Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer.
    Gynecol Oncol. 2018 Apr 4. pii: S0090-8258(18)30238.
    >> Share

  591. MANRRIQUEZ E, Chapman JS, Mak J, Blanco AM, et al
    Disparities in genetics assessment for women with ovarian cancer: Can we do better?
    Gynecol Oncol. 2018;149:84-88.
    >> Share

  592. DILLEY S, Erickson BK, Phillips CE, Kennemer CR, et al
    Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?
    Gynecol Oncol. 2018;149:49-52.
    >> Share

  593. COWAN RA, Tseng J, Ali N, Dearie H, et al
    Exploring the impact of income and race on survival for women with advanced ovarian cancer undergoing primary debulking surgery at a high-volume center.
    Gynecol Oncol. 2018;149:43-48.
    >> Share

  594. MOORE KN, Mirza MR, Matulonis UA
    The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    Gynecol Oncol. 2018;149:214-220.
    >> Share

    March 2018
  595. BONHOF CS, Mols F, Vos MC, Pijnenborg JMA, et al
    Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study.
    Gynecol Oncol. 2018 Mar 28. pii: S0090-8258(18)30232.
    >> Share

  596. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Efficacy of soft coagulation in retroperitoneal lymphadenectomy for ovarian cancer.
    Gynecol Oncol. 2018 Mar 21. pii: S0090-8258(18)30231.
    >> Share

  597. LONG J, Zhu JY, Liu YB, Fu K, et al
    Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30176.
    >> Share

  598. MCDONALD JF
    Back to the future - The integration of big data with machine learning is re-establishing the importance of predictive correlations in ovarian cancer diagnostics and therapeutics.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30233.
    >> Share

  599. WILSON AJ, Stubbs M, Liu P, Ruggeri B, et al
    The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30229.
    >> Share

  600. KIM J, Kim S, Lee HS, Yang W, et al
    Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30132.
    >> Share

  601. HAN C, Bellone S, Siegel ER, Altwerger G, et al
    A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30230.
    >> Share

  602. IDAHL A, Hermansson A, Lalos A
    Social support and ovarian cancer incidence - A Swedish prospective population-based study.
    Gynecol Oncol. 2018 Mar 17. pii: S0090-8258(18)30214.
    >> Share

  603. CARLTON AL, Illendula A, Gao Y, Llaneza DC, et al
    Small molecule inhibition of the CBFbeta/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition.
    Gynecol Oncol. 2018 Mar 15. pii: S0090-8258(18)30174.
    >> Share

  604. ESKANDER RN, Kauderer J, Tewari KS, Mannel RS, et al
    Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 Mar 14. pii: S0090-8258(18)30216.
    >> Share

  605. UCCELLA S, Mele MC, Quagliozzi L, Rinninella E, et al
    Assessment of preoperative nutritional status using BIA-derived phase angle (PhA) in patients with advanced ovarian cancer: Correlation with the extent of cytoreduction and complications.
    Gynecol Oncol. 2018 Mar 14. pii: S0090-8258(18)30215.
    >> Share

  606. MATSUO K, Yabuno A, Hom MS, Shida M, et al
    Significance of abnormal peritoneal cytology on survival of women with stage I-II endometrioid endometrial cancer.
    Gynecol Oncol. 2018 Mar 12. pii: S0090-8258(18)30131.
    >> Share

  607. GOSTNER JM, Obermayr E, Braicu IE, Concin N, et al
    Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium.
    Gynecol Oncol. 2018 Mar 9. pii: S0090-8258(18)30139.
    >> Share

  608. SCHORGE JO, Bregar AJ, Durfee J, Berkowitz RS, et al
    Meigs to modern times: The evolution of debulking surgery in advanced ovarian cancer.
    Gynecol Oncol. 2018 Mar 7. pii: S0090-8258(18)30142.
    >> Share

  609. SCHUURMAN MS, Kruitwagen RFPM, Portielje JEA, Roes EM, et al
    Treatment and outcome of elderly patients with advanced stage ovarian cancer: A nationwide analysis.
    Gynecol Oncol. 2018 Mar 4. pii: S0090-8258(18)30136.
    >> Share

  610. LIAO CI, Chow S, Chen LM, Kapp DS, et al
    Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US.
    Gynecol Oncol. 2018 Mar 4. pii: S0090-8258(18)30069.
    >> Share

  611. BUSKWOFIE A, Huang Y, Tergas AI, Hou JY, et al
    Impact of hospital volume on racial disparities and outcomes for endometrial cancer.
    Gynecol Oncol. 2018 Mar 2. pii: S0090-8258(18)30138.
    >> Share

  612. POWELL CB, Alabaster A, Stoller N, Armstrong MA, et al
    Bone loss in women with BRCA1 and BRCA2 mutations.
    Gynecol Oncol. 2018;148:535-539.
    >> Share

  613. FILIPPOV-LEVY N, Cohen-Schussheim H, Trope CG, Hetland Falkenthal TE, et al
    Expression and clinical role of long non-coding RNA in high-grade serous carcinoma.
    Gynecol Oncol. 2018;148:559-566.
    >> Share

    February 2018
  614. XIAO X, Dong D, He W, Song L, et al
    Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    Gynecol Oncol. 2018 Feb 26. pii: S0090-8258(18)30128.
    >> Share

  615. WEAVER DT, Raphel TJ, Melamed A, Rauh-Hain JA, et al
    Modeling treatment outcomes for patients with advanced ovarian cancer: Projected benefits of a test to optimize treatment selection.
    Gynecol Oncol. 2018 Feb 24. pii: S0090-8258(18)30126.
    >> Share

  616. BARRINGTON DA, Champion ML, Boitano TKL, Walters-Haygood CL, et al
    Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
    Gynecol Oncol. 2018 Feb 24. pii: S0090-8258(18)30133.
    >> Share

  617. HUVILA J, Laajala TD, Edqvist PH, Mardinoglu A, et al
    Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma.
    Gynecol Oncol. 2018 Feb 24. pii: S0090-8258(18)30135.
    >> Share

  618. JAREID M, Thalabard JC, Aarflot M, Bovelstad HM, et al
    Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study.
    Gynecol Oncol. 2018 Feb 23. pii: S0090-8258(18)30125.
    >> Share

  619. KELLENBERGER LD, Petrik J
    Hyperglycemia promotes insulin-independent ovarian tumor growth.
    Gynecol Oncol. 2018 Feb 17. pii: S0090-8258(18)30122.
    >> Share

  620. OZA A, Kaye S, Van Tornout J, Sessa C, et al
    Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
    Gynecol Oncol. 2018 Feb 14. pii: S0090-8258(18)30058.
    >> Share

  621. LI Y, Wu T, Wang Y, Yang L, et al
    gamma-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
    Gynecol Oncol. 2018 Feb 8. pii: S0090-8258(18)30062.
    >> Share

  622. CRANE EK, Brown J
    Early stage mucinous ovarian cancer: A review.
    Gynecol Oncol. 2018 Feb 8. pii: S0090-8258(18)30074.
    >> Share

  623. DESAI P, Wallace R, Anderson ML, Howard BV, et al
    An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative.
    Gynecol Oncol. 2018 Feb 5. pii: S0090-8258(18)30038.
    >> Share

  624. SWANSON CL, Kumar A, Maharaj JM, Kemppainen JL, et al
    Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis.
    Gynecol Oncol. 2018 Feb 3. pii: S0090-8258(18)30072.
    >> Share

  625. MILLER KR, Patel JN, Zhang Q, Norris EJ, et al
    HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Gynecol Oncol. 2018 Feb 2. pii: S0090-8258(18)30061.
    >> Share

  626. NAUMANN RW, Brown J
    Ovarian cancer screening with the Risk of Ovarian Cancer Algorithm (ROCA): Good, bad, or just expensive?
    Gynecol Oncol. 2018 Feb 1. pii: S0090-8258(18)30068.
    >> Share

    January 2018
  627. DEWDNEY SB, Dancisak AC, Lachance JA, Grendys EC Jr, et al
    Society of Gynecologic Oncology Clinical Outcomes Registry: From small beginnings come great things.
    Gynecol Oncol. 2018 Jan 30. pii: S0090-8258(18)30060.
    >> Share

  628. KESSOUS R, Octeau D, Klein K, Tonin PN, et al
    Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.
    Gynecol Oncol. 2018 Jan 29. pii: S0090-8258(18)30055.
    >> Share

  629. HENRY CE, Llamosas E, Daniels B, Coopes A, et al
    ROR1 and ROR2 play distinct and opposing roles in endometrial cancer.
    Gynecol Oncol. 2018 Jan 29. pii: S0090-8258(18)30064.
    >> Share

  630. NITECKI R, Diver EJ, Kamdar MM, Boruta DM 2nd, et al
    Patterns of palliative care referral in ovarian cancer: A single institution 5year retrospective analysis.
    Gynecol Oncol. 2018 Jan 27. pii: S0090-8258(18)30056.
    >> Share

  631. SAMIMI G, Trabert B, Duggan MA, Robinson JL, et al
    Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.
    Gynecol Oncol. 2018 Jan 25. pii: S0090-8258(18)30048.
    >> Share

  632. GRAY HJ, Bell-McGuinn K, Fleming GF, Cristea M, et al
    Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    Gynecol Oncol. 2018 Jan 15. pii: S0090-8258(17)31620.
    >> Share

  633. BERGSTROM J, Aloisi A, Armbruster S, Yen TT, et al
    Minimally invasive hysterectomy surgery rates for endometrial cancer performed at National Comprehensive Cancer Network (NCCN) Centers.
    Gynecol Oncol. 2018 Jan 12. pii: S0090-8258(18)30002.
    >> Share

  634. TRABERT B, Aarestrup J, Ulrich LG, Wentzensen N, et al
    Birth weight and the risk of histological subtypes of ovarian and endometrial cancers: Results from the Copenhagen School Health Records Register.
    Gynecol Oncol. 2018 Jan 10. pii: S0090-8258(17)31622.
    >> Share

  635. SAED GM, Fletcher NM, Diamond MP, Morris RT, et al
    Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target.
    Gynecol Oncol. 2018 Jan 9. pii: S0090-8258(17)31606.
    >> Share

  636. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Retroperitoneal lymphadenectomy for ovarian cancer with double inferior vena cava.
    Gynecol Oncol. 2018 Jan 5. pii: S0090-8258(17)31619.
    >> Share

  637. MUKERJI B, Baptiste C, Chen L, Tergas AI, et al
    Racial disparities in young women with endometrial cancer.
    Gynecol Oncol. 2018 Jan 4. pii: S0090-8258(17)31623.
    >> Share

    December 2017
  638. TOUHAMI O, Gregoire J, Renaud MC, Sebastianelli A, et al
    The utility of sentinel lymph node mapping in the management of endometrial atypical hyperplasia.
    Gynecol Oncol. 2017 Dec 28. pii: S0090-8258(17)31617.
    >> Share

  639. SOISSON S, Ganz PA, Gaffney D, Rowe K, et al
    Long-term, adverse genitourinary outcomes among endometrial cancer survivors in a large, population-based cohort study.
    Gynecol Oncol. 2017 Dec 27. pii: S0090-8258(17)31616.
    >> Share

  640. GEPPERT B, Lonnerfors C, Bollino M, Persson J, et al
    Sentinel lymph node biopsy in endometrial cancer-Feasibility, safety and lymphatic complications.
    Gynecol Oncol. 2017 Dec 20. pii: S0090-8258(17)31602.
    >> Share

  641. TRAN AQ, Erim DO, Sullivan SA, Cole AL, et al
    Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.
    Gynecol Oncol. 2017 Dec 19. pii: S0090-8258(17)31598.
    >> Share

  642. MIAO M, Deng G, Luo S, Zhou J, et al
    A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
    Gynecol Oncol. 2017 Dec 13. pii: S0090-8258(17)31596.
    >> Share

  643. BERNARDS SS, Pennington KP, Harrell MI, Agnew KJ, et al
    Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
    Gynecol Oncol. 2017 Dec 9. pii: S0090-8258(17)31551.
    >> Share

  644. KIM SI, Lee JW, Lee M, Kim HS, et al
    Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
    Gynecol Oncol. 2017 Dec 9. pii: S0090-8258(17)31552.
    >> Share

  645. SMITH D, Stewart CJR, Clarke EM, Lose F, et al
    ER and PR expression and survival after endometrial cancer.
    Gynecol Oncol. 2017 Dec 4. pii: S0090-8258(17)31537.
    >> Share

  646. URBAN RR, He H, Alfonso R, Hardesty MM, et al
    The end of life costs for Medicare patients with advanced ovarian cancer.
    Gynecol Oncol. 2017 Dec 3. pii: S0090-8258(17)31533.
    >> Share

  647. BITLER BG, Watson ZL, Wheeler LJ, Behbakht K, et al
    PARP inhibitors: Clinical utility and possibilities of overcoming resistance.
    Gynecol Oncol. 2017;147:695-704.
    >> Share

  648. KUMAR A, Hurtt CC, Cliby WA, Martin JR, et al
    Concomitant venous thromboembolism at the time of primary EOC diagnosis: Perioperative outcomes and survival analyses.
    Gynecol Oncol. 2017;147:514-520.
    >> Share

  649. REISER E, Aust S, Seebacher V, Reinthaller A, et al
    Preoperative C-reactive protein serum levels as a predictive diagnostic marker in patients with adnexal masses.
    Gynecol Oncol. 2017;147:690-694.
    >> Share

    November 2017
  650. HAMILTON CA, Miller A, Casablanca Y, Horowitz NS, et al
    Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.
    Gynecol Oncol. 2017 Nov 28. pii: S0090-8258(17)31528.
    >> Share

  651. ZHU J, Chen Z, Yong L
    Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer.
    Gynecol Oncol. 2017 Nov 27. pii: S0090-8258(17)31538.
    >> Share

  652. GULERIA S, Jensen A, Kjaer SK
    Risk of borderline ovarian tumors among women with benign ovarian tumors: A cohort study.
    Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31534.
    >> Share

  653. HOROWITZ NS, Larry Maxwell G, Miller A, Hamilton CA, et al
    Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.
    Gynecol Oncol. 2017 Nov 22. pii: S0090-8258(17)31371.
    >> Share

  654. LEE YJ, Chung YS, Lee JY, Nam EJ, et al
    Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer.
    Gynecol Oncol. 2017 Nov 21. pii: S0090-8258(17)31532.
    >> Share

  655. TOZZI R, Casarin J, Garruto-Campanile R, Majd HS, et al
    Morbidity and reversal rate of ileostomy after bowel resection during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer.
    Gynecol Oncol. 2017 Nov 20. pii: S0090-8258(17)31527.
    >> Share

  656. HEINZELMANN-SCHWARZ V, Knipprath Meszaros A, Stadlmann S, Jacob F, et al
    Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.
    Gynecol Oncol. 2017 Nov 17. pii: S0090-8258(17)31458.
    >> Share

  657. CHAMPER M, Huang Y, Hou JY, Tergas AI, et al
    Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence.
    Gynecol Oncol. 2017 Nov 15. pii: S0090-8258(17)31504.
    >> Share

  658. SHAH JS, Gard GB, Yang J, Maidens J, et al
    Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer.
    Gynecol Oncol. 2017 Nov 10. pii: S0090-8258(17)31500.
    >> Share

  659. COSGROVE CM, Tritchler DL, Cohn DE, Mutch DG, et al
    An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
    Gynecol Oncol. 2017 Nov 10. pii: S0090-8258(17)31459.
    >> Share

  660. TIMMERMANS M, Schuurman MS, Ho VKY, Massuger LF, et al
    Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients' probability of undergoing surgery.
    Gynecol Oncol. 2017 Nov 9. pii: S0090-8258(17)31505.
    >> Share

  661. MERT I, Kumar A, Sheedy SP, Weaver AL, et al
    Clinical significance of enlarged cardiophrenic lymph nodes in advanced ovarian cancer: Implications for survival.
    Gynecol Oncol. 2017 Nov 9. pii: S0090-8258(17)31446.
    >> Share

  662. HOPPENOT C, Eckert MA, Tienda SM, Lengyel E, et al
    Who are the long-term survivors of high grade serous ovarian cancer?
    Gynecol Oncol. 2017 Nov 8. pii: S0090-8258(17)31454.
    >> Share

  663. HINCHCLIFF E, Melamed A, Bregar A, Diver E, et al
    Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
    Gynecol Oncol. 2017 Nov 8. pii: S0090-8258(17)31460.
    >> Share

  664. CHAN JK, Kapp DS
    Clear Cell Ovarian Cancer: Optimum Management and Prognosis Remain Hazy.
    Gynecol Oncol. 2017;147:237-239.
    >> Share

  665. ALTMAN AD, McGee J, May T, Lane K, et al
    Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study.
    Gynecol Oncol. 2017;147:257-261.
    >> Share

    October 2017
  666. RONCOLATO FT, Berton-Rigaud D, O'Connell R, Lanceley A, et al
    Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
    Gynecol Oncol. 2017 Oct 26. pii: S0090-8258(17)31422.
    >> Share

  667. LIN DI, Chudnovsky Y, Duggan B, Zajchowski D, et al
    Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.
    Gynecol Oncol. 2017 Oct 25. pii: S0090-8258(17)31355.
    >> Share

  668. SHALOWITZ DI, Nivasch E, Burger RA, Schapira MM, et al
    Are patients willing to travel for better ovarian cancer care?
    Gynecol Oncol. 2017 Oct 24. pii: S0090-8258(17)31421.
    >> Share

  669. YI Y, Tsai SH, Cheng JC, Wang EY, et al
    APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner.
    Gynecol Oncol. 2017 Oct 24. pii: S0090-8258(17)31419.
    >> Share

  670. JONES MR, Kamara D, Karlan BY, Pharoah PDP, et al
    Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction.
    Gynecol Oncol. 2017 Oct 17. pii: S0090-8258(17)31361.
    >> Share

  671. ARIMA R, Hautakoski A, Marttila M, Arffman M, et al
    Cause-specific mortality in endometrioid endometrial cancer patients with type 2 diabetes using metformin or other types of antidiabetic medication.
    Gynecol Oncol. 2017 Oct 17. pii: S0090-8258(17)31417.
    >> Share

  672. DOCKERY LE, Tew WP, Ding K, Moore KN, et al
    Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.
    Gynecol Oncol. 2017 Oct 13. pii: S0090-8258(17)31364.
    >> Share

  673. SCHULTZ KAP, Harris AK, Finch M, Dehner LP, et al
    DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry.
    Gynecol Oncol. 2017 Oct 13. pii: S0090-8258(17)31358.
    >> Share

  674. POZZAR RA, Berry DL
    Patient-centered research priorities in ovarian cancer: A systematic review of potential determinants of guideline care.
    Gynecol Oncol. 2017 Oct 10. pii: S0090-8258(17)31365.
    >> Share

  675. XIA Z, Cochrane DR, Anglesio MS, Wang YK, et al
    LINE-1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers.
    Gynecol Oncol. 2017 Oct 9. pii: S0090-8258(17)31356.
    >> Share

  676. NASIOUDIS D, Frey MK, Chapman-Davis E, Caputo TA, et al
    Fertility-preserving surgery for advanced stage ovarian germ cell tumors.
    Gynecol Oncol. 2017 Oct 9. pii: S0090-8258(17)31370.
    >> Share

  677. PEPIN K, Bregar A, Davis M, Melamed A, et al
    Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery.
    Gynecol Oncol. 2017 Oct 4. pii: S0090-8258(17)31352.
    >> Share

  678. MATSUO K, Machida H, Frimer M, Marcus JZ, et al
    Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer.
    Gynecol Oncol. 2017 Oct 3. pii: S0090-8258(17)31351.
    >> Share

    September 2017
  679. DEVOR EJ, Miecznikowski J, Schickling BM, Gonzalez-Bosquet J, et al
    Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Sep 29. pii: S0090-8258(17)31349.
    >> Share

  680. DUCIE JA, Eriksson AGZ, Ali N, McGree ME, et al
    Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease.
    Gynecol Oncol. 2017 Sep 28. pii: S0090-8258(17)31354.
    >> Share

  681. QIU C, Lu N, Wang X, Zhang Q, et al
    Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium.
    Gynecol Oncol. 2017 Sep 28. pii: S0090-8258(17)31353.
    >> Share

  682. TORRES D, Kumar A, Wallace SK, Bakkum-Gamez JN, et al
    Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer.
    Gynecol Oncol. 2017 Sep 27. pii: S0090-8258(17)31345.
    >> Share

  683. BARBER EL, Rossi EC, Gehrig PA
    Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival?
    Gynecol Oncol. 2017 Sep 20. pii: S0090-8258(17)31340.
    >> Share

  684. RUSTIN G, Vergote I, Micha JP, Duska LR, et al
    A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.
    Gynecol Oncol. 2017 Sep 18. pii: S0090-8258(17)31264.
    >> Share

  685. MOORE KN, Tritchler D, Kaufman KM, Lankes H, et al
    Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Sep 18. pii: S0090-8258(17)31261.
    >> Share

  686. LILYQUIST J, LaDuca H, Polley E, Davis BT, et al
    Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls.
    Gynecol Oncol. 2017 Sep 7. pii: S0090-8258(17)31268.
    >> Share

  687. PISU M, Kenzik KM, Rim SH, Funkhouser EM, et al
    Values and worries of ovarian cancer patients.
    Gynecol Oncol. 2017 Sep 6. pii: S0090-8258(17)31267.
    >> Share

  688. COWAN RA, Tseng J, Murthy V, Srivastava R, et al
    Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.
    Gynecol Oncol. 2017 Sep 6. pii: S0090-8258(17)31270.
    >> Share

  689. OZA AM, Tinker AV, Oaknin A, Shapira-Frommer R, et al
    Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
    Gynecol Oncol. 2017 Sep 4. pii: S0090-8258(17)31260.
    >> Share

  690. HAVRILESKY LJ
    The costs of adding laparoscopy to the management of advanced stage epithelial ovarian cancer.
    Gynecol Oncol. 2017;146:441-442.
    >> Share

    August 2017
  691. WANG X, Ivan M, Hawkins SM
    The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer.
    Gynecol Oncol. 2017 Aug 30. pii: S0090-8258(17)31266.
    >> Share

  692. ZHU Z, Lou C, Zheng Z, Zhu R, et al
    ZFP403, a novel tumor suppressor, inhibits the proliferation and metastasis in ovarian cancer.
    Gynecol Oncol. 2017 Aug 30. pii: S0090-8258(17)31263.
    >> Share

  693. LAGO V, Domingo S, Matute L, Padilla P, et al
    Ghost ileostomy in advanced ovarian cancer.
    Gynecol Oncol. 2017 Aug 29. pii: S0090-8258(17)31255.
    >> Share

  694. GOFF BA, Agnew K, Neradilek MB, Gray HJ, et al
    Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass.
    Gynecol Oncol. 2017 Aug 28. pii: S0090-8258(17)31258.
    >> Share

  695. DUAN H, Yan Z, Chen W, Wu Y, et al
    TET1 inhibits EMT of ovarian cancer cells through activating Wnt/beta-catenin signaling inhibitors DKK1 and SFRP2.
    Gynecol Oncol. 2017 Aug 26. pii: S0090-8258(17)31248.
    >> Share

  696. HERZOG TJ, Ison G, Alvarez RD, Balasubramaniam S, et al
    FDA ovarian cancer clinical trial endpoints workshop.
    Gynecol Oncol. 2017 Aug 24. pii: S0090-8258(17)31250.
    >> Share

  697. MARTIN LP, Konner JA, Moore KN, Seward SM, et al
    Characterization of folate receptor alpha (FRalpha) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRalpha-targeting antibody-drug conjugate mirvetuximab soravtansine.
    Gynecol Oncol. 2017 Aug 24. pii: S0090-8258(17)31253.
    >> Share

  698. PEARL ML, Dong H, Zhao Q, Tulley S, et al
    iCTC drug resistance (CDR) Testing ex vivo for evaluation of available therapies to treat patients with epithelial ovarian cancer.
    Gynecol Oncol. 2017 Aug 19. pii: S0090-8258(17)31256.
    >> Share

  699. MELAMED A, Manning-Geist B, Bregar AJ, Diver EJ, et al
    Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Gynecol Oncol. 2017 Aug 16. pii: S0090-8258(17)31225.
    >> Share

  700. OLIVER KE, Brady WE, Birrer M, Gershenson DM, et al
    An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
    Gynecol Oncol. 2017 Aug 11. pii: S0090-8258(17)31226.
    >> Share

  701. NASIOUDIS D, Chapman-Davis E, Frey MK, Caputo TA, et al
    Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base.
    Gynecol Oncol. 2017 Aug 10. pii: S0090-8258(17)31251.
    >> Share

  702. THAKER PH, Brady WE, Lankes HA, Odunsi K, et al
    A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary perito
    Gynecol Oncol. 2017 Aug 9. pii: S0090-8258(17)31186.
    >> Share

  703. FORTNER RT, Damms-Machado A, Kaaks R
    Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.
    Gynecol Oncol. 2017 Aug 8. pii: S0090-8258(17)31178.
    >> Share

  704. KNAPP P, Bodnar L, Blachnio-Zabielska A, Swiderska M, et al
    Plasma and ovarian tissue sphingolipids profiling in patients with advanced ovarian cancer.
    Gynecol Oncol. 2017 Aug 8. pii: S0090-8258(17)31183.
    >> Share

  705. TATE S, Kato K, Nishikimi K, Matsuoka A, et al
    Survival and safety associated with aggressive surgery for stage III/IV epithelial ovarian cancer: A single institution observation study.
    Gynecol Oncol. 2017 Aug 8. pii: S0090-8258(17)31176.
    >> Share

  706. BOGANI G, Tagliabue E, Ditto A, Signorelli M, et al
    Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses.
    Gynecol Oncol. 2017 Aug 2. pii: S0090-8258(17)31179.
    >> Share

  707. CRIM A, Rowland M, Ruskin R, Dvorak J, et al
    Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women.
    Gynecol Oncol. 2017;146:268-272.
    >> Share

    July 2017
  708. CHOI C, Kim WY, Lee DH, Oh SS, et al
    Cytoreduction of bulky para-aortic lymphadenopathy from metastatic ovarian cancer.
    Gynecol Oncol. 2017 Jul 31. pii: S0090-8258(17)31173.
    >> Share

  709. FLEMING ND, Coleman RL, Tung C, Westin SN, et al
    Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer.
    Gynecol Oncol. 2017 Jul 31. pii: S0090-8258(17)31177.
    >> Share

  710. FADER AN, Bergstrom J, Jernigan A, Tanner EJ 3rd, et al
    Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
    Gynecol Oncol. 2017 Jul 30. pii: S0090-8258(17)31167.
    >> Share

  711. HOGEN L, Brar H, Covens A, Bassiouny D, et al
    Is adjuvant chemotherapy beneficial for surgical stage I ovarian clear cell carcinoma?
    Gynecol Oncol. 2017 Jul 28. pii: S0090-8258(17)31168.
    >> Share

  712. COHN DE, Sill MW, Walker JL, O'Malley D, et al
    Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin(R)) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Jul 27. pii: S0090-8258(17)31175.
    >> Share

  713. MILLER EM, Tymon-Rosario J, Xie X, Xue X, et al
    Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population.
    Gynecol Oncol. 2017 Jul 24. pii: S0090-8258(17)31169.
    >> Share

  714. PHIPPEN NT, Secord AA, Wolf S, Samsa G, et al
    Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.
    Gynecol Oncol. 2017 Jul 22. pii: S0090-8258(17)31138.
    >> Share

  715. ADAM JP, Boumedien F, Letarte N, Provencher D, et al
    Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.
    Gynecol Oncol. 2017 Jul 21. pii: S0090-8258(17)31160.
    >> Share

  716. KUMAR A, Langstraat CL, DeJong SR, McGree ME, et al
    Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer.
    Gynecol Oncol. 2017 Jul 19. pii: S0090-8258(17)31163.
    >> Share

  717. KHATIB G, Guzel AB, Gulec UK, Vardar MA, et al
    A novel technique: Carbon dioxide gas-assisted total peritonectomy, diaphragm and intestinal meso stripping in open surgery for advanced ovarian cancer (Cukurova technique).
    Gynecol Oncol. 2017 Jul 15. pii: S0090-8258(17)31172.
    >> Share

  718. FALCONE F, Scambia G, Benedetti Panici P, Signorelli M, et al
    Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study.
    Gynecol Oncol. 2017 Jul 14. pii: S0090-8258(17)31025.
    >> Share

  719. NASIOUDIS D, Chapman-Davis E, Frey MK, Caputo TA, et al
    Should epithelial ovarian carcinoma metastatic to the inguinal lymph nodes be assigned stage IVB?
    Gynecol Oncol. 2017 Jul 14. pii: S0090-8258(17)31161.
    >> Share

  720. PALEARI L, Gandini S, Provinciali N, Puntoni M, et al
    Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis.
    Gynecol Oncol. 2017 Jul 10. pii: S0090-8258(17)30977.
    >> Share

  721. MENDERES G, Bonazzoli E, Bellone S, Altwerger G, et al
    Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.
    Gynecol Oncol. 2017 Jul 10. pii: S0090-8258(17)31026.
    >> Share

  722. KRISTELEIT R, Davidenko I, Shirinkin V, El-Khouly F, et al
    A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.
    Gynecol Oncol. 2017 Jul 8. pii: S0090-8258(17)31022.
    >> Share

  723. YUAN X, Zhang J, Li D, Mao Y, et al
    Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2017 Jul 8. pii: S0090-8258(17)31024.
    >> Share

  724. GREENWADE MM, Moore KN, Gillen JM, Ding K, et al
    Factors influencing clinical trial enrollment among ovarian cancer patients.
    Gynecol Oncol. 2017 Jul 6. pii: S0090-8258(17)30976.
    >> Share

  725. MATZ M, Coleman MP, Carreira H, Salmeron D, et al
    Erratum to "Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 396-404].
    Gynecol Oncol. 2017 Jul 5. pii: S0090-8258(17)30974.
    >> Share

  726. SON JH, Chang SJ, Ryu HS
    Porta hepatis debulking procedures as part of primary cytoreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2017 Jul 5. pii: S0090-8258(17)30978.
    >> Share

  727. MATZ M, Coleman MP, Sant M, Chirlaque MD, et al
    Erratum to "The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 405-413].
    Gynecol Oncol. 2017 Jul 5. pii: S0090-8258(17)30973.
    >> Share

    June 2017
  728. KAWABATA A, Yanaihara N, Nagata C, Saito M, et al
    Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.
    Gynecol Oncol. 2017 Jun 30. pii: S0090-8258(17)30968.
    >> Share

  729. SUN Z, Gilbert L, Ciampi A, Basso O, et al
    Recruitment challenges in clinical research: Survey of potential participants in a diagnostic study of ovarian cancer.
    Gynecol Oncol. 2017 Jun 27. pii: S0090-8258(17)30962.
    >> Share

  730. VAN DE VRIE R, van Meurs HS, Rutten MJ, Naaktgeboren CA, et al
    Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer.
    Gynecol Oncol. 2017 Jun 20. pii: S0090-8258(17)30960.
    >> Share

  731. ARIMA R, Marttila M, Hautakoski A, Arffman M, et al
    Antidiabetic medication, statins and the risk of endometrioid endometrial cancer in patients with type 2 diabetes.
    Gynecol Oncol. 2017 Jun 20. pii: S0090-8258(17)30952.
    >> Share

  732. MOSS HA, Havrilesky LJ, Chino J
    Insurance coverage among women diagnosed with a gynecologic malignancy before and after implementation of the Affordable Care Act.
    Gynecol Oncol. 2017 Jun 19. pii: S0090-8258(17)30953.
    >> Share

  733. SOOVARES P, Pasanen A, Butzow R, Lassus H, et al
    L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma.
    Gynecol Oncol. 2017 Jun 15. pii: S0090-8258(17)30939.
    >> Share

  734. SZENDER JB, Emmons T, Belliotti S, Dickson D, et al
    Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study.
    Gynecol Oncol. 2017 Jun 14. pii: S0090-8258(17)30937.
    >> Share

  735. BEDNAR EM, Oakley HD, Sun CC, Burke CC, et al
    A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
    Gynecol Oncol. 2017 Jun 10. pii: S0090-8258(17)30893.
    >> Share

  736. GRIMM C, Harter P, Alesina PF, Prader S, et al
    The impact of type and number of bowel resections on anastomotic leakage risk in advanced ovarian cancer surgery.
    Gynecol Oncol. 2017 Jun 10. pii: S0090-8258(17)30936.
    >> Share

  737. FREY MK, Ellis AE, Koontz LM, Shyne S, et al
    Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum.
    Gynecol Oncol. 2017 Jun 8. pii: S0090-8258(17)30885.
    >> Share


  738. A systematic review of patient values, preferences and expectations for the treatment of recurrent ovarian cancer.
    Gynecol Oncol. 2017 Jun 7. pii: S0090-8258(17)30895.
    >> Share

  739. VOGEL TJ, Goodman MT, Li AJ, Jeon CY, et al
    Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.
    Gynecol Oncol. 2017 Jun 5. pii: S0090-8258(17)30848.
    >> Share

  740. RANDALL LM, Pothuri B, Swisher EM, Diaz JP, et al
    Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper.
    Gynecol Oncol. 2017 Jun 5. pii: S0090-8258(17)30897.
    >> Share

  741. SINNO AK, Li X, Thompson RE, Tanner EJ 3rd, et al
    Trends and factors associated with radical cytoreductive surgery in the United States: A case for centralized care.
    Gynecol Oncol. 2017;145:493-499.
    >> Share

  742. BRACHOVA P, Alvarez NS, Van Voorhis BJ, Christenson LK, et al
    Cytidine deaminase Apobec3a induction in fallopian epithelium after exposure to follicular fluid.
    Gynecol Oncol. 2017;145:577-583.
    >> Share

  743. NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
    Complete resection of locally advanced ovarian carcinoma fixed to the pelvic sidewall and involving external and internal iliac vessels.
    Gynecol Oncol. 2017 Jun 1. pii: S0090-8258(17)30887.
    >> Share

    May 2017
  744. DILLEY SE, Havrilesky LJ, Bakkum-Gamez J, Cohn DE, et al
    Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention.
    Gynecol Oncol. 2017 May 31. pii: S0090-8258(17)30890.
    >> Share

  745. PLANTE M, Stanleigh J, Renaud MC, Sebastianelli A, et al
    Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: Does adjuvant treatment matter?
    Gynecol Oncol. 2017 May 31. pii: S0090-8258(17)30880.
    >> Share

  746. HOLLOWAY RW, Abu-Rustum NR, Backes FJ, Boggess JF, et al
    Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations.
    Gynecol Oncol. 2017 May 28. pii: S0090-8258(17)30883.
    >> Share

  747. EGGINK FA, Mom CH, Boll D, Ezendam NPM, et al
    Compliance with adjuvant treatment guidelines in endometrial cancer: room for improvement in high risk patients.
    Gynecol Oncol. 2017 May 25. pii: S0090-8258(17)30881.
    >> Share

  748. JAMIESON A, Sykes P, Eva L, Bergzoll C, et al
    Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence.
    Gynecol Oncol. 2017 May 23. pii: S0090-8258(17)30879.
    >> Share

  749. MALAGON-BLACKWELL EM, Seagle BL, Nieves-Neira W, Shahabi S, et al
    The Hispanic Paradox in endometrial cancer: A National Cancer Database study.
    Gynecol Oncol. 2017 May 23. pii: S0090-8258(17)30882.
    >> Share

  750. FABER MT, Frederiksen K, Jensen A, Aarslev PB, et al
    Time trends in the incidence of hysterectomy-corrected overall, type 1 and type 2 endometrial cancer in Denmark 1978-2014.
    Gynecol Oncol. 2017 May 23. pii: S0090-8258(17)30854.
    >> Share

  751. MERT I, Chhina J, Allo G, Dai J, et al
    Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
    Gynecol Oncol. 2017 May 22. pii: S0090-8258(17)30871.
    >> Share

  752. SEAGLE BL, Ann P, Butler S, Shahabi S, et al
    Ovarian granulosa cell tumor: A National Cancer Database study.
    Gynecol Oncol. 2017 May 19. pii: S0090-8258(17)30873.
    >> Share

  753. REYES HD, Miecznikowski J, Gonzalez-Bosquet J, Devor EJ, et al
    High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.
    Gynecol Oncol. 2017 May 19. pii: S0090-8258(17)30870.
    >> Share

  754. DINKIC C, Eichbaum M, Schmidt M, Grischke EM, et al
    Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
    Gynecol Oncol. 2017 May 18. pii: S0090-8258(17)30852.
    >> Share

  755. SOLIMAN PT, Westin SN, Dioun S, Sun CC, et al
    A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer.
    Gynecol Oncol. 2017 May 18. pii: S0090-8258(17)30855.
    >> Share

  756. LUTGENDORF SK, Shinn E, Carter J, Leighton S, et al
    Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach.
    Gynecol Oncol. 2017 May 17. pii: S0090-8258(17)30846.
    >> Share

  757. ERIKSSON AGZ, Graul A, Yu MC, Halko A, et al
    Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes.
    Gynecol Oncol. 2017 May 17. pii: S0090-8258(17)30875.
    >> Share

  758. BARBER EL, Doll KM, Gehrig PA
    Hospital readmission after ovarian cancer surgery: Are we measuring surgical quality?
    Gynecol Oncol. 2017 May 15. pii: S0090-8258(17)30851.
    >> Share

  759. EDMONDSON RJ, Crosbie EJ, Nickkho-Amiry M, Kaufmann A, et al
    Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
    Gynecol Oncol. 2017 May 13. pii: S0090-8258(17)30853.
    >> Share

  760. COHEN JG, Prendergast E, Geddings JE, Walts AE, et al
    Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer.
    Gynecol Oncol. 2017 May 10. pii: S0090-8258(17)30802.
    >> Share

  761. GARCIA C, Yao A, Camacho F, Balkrishnan R, et al
    A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer.
    Gynecol Oncol. 2017 May 9. pii: S0090-8258(17)30847.
    >> Share

  762. TANENBAUM LM, Mantzavinou A, Subramanyam KS, Del Carmen MG, et al
    Ovarian cancer spheroid shrinkage following continuous exposure to cisplatin is a function of spheroid diameter.
    Gynecol Oncol. 2017 May 9. pii: S0090-8258(17)30795.
    >> Share

  763. ENG KH, Morrell K, Starbuck K, Spring-Robinson C, et al
    Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer.
    Gynecol Oncol. 2017 May 8. pii: S0090-8258(17)30844.
    >> Share

  764. DE DONATO M, Petrillo M, Martinelli E, Filippetti F, et al
    Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancer.
    Gynecol Oncol. 2017 May 8. pii: S0090-8258(17)30806.
    >> Share

  765. GRABOSCH S, Tseng G, Edwards RP, Lankes HA, et al
    Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.
    Gynecol Oncol. 2017 May 5. pii: S0090-8258(17)30787.
    >> Share

  766. MENDERES G, Bonazzoli E, Bellone S, Black J, et al
    SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.
    Gynecol Oncol. 2017 May 1. pii: S0090-8258(17)30804.
    >> Share

    April 2017
  767. COLON-OTERO G, Weroha SJ, Foster NR, Haluska P, et al
    Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.
    Gynecol Oncol. 2017 Apr 28. pii: S0090-8258(17)30801.
    >> Share

  768. VENERIS JT, Darcy KM, Mhawech-Fauceglia P, Tian C, et al
    High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer.
    Gynecol Oncol. 2017 Apr 26. pii: S0090-8258(17)30793.
    >> Share

  769. BOOKMAN MA, Tyczynski JE, Espirito JL, Wilson TW, et al
    Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
    Gynecol Oncol. 2017 Apr 26. pii: S0090-8258(17)30792.
    >> Share

  770. PETERS ML, Garber JE, Tung N
    Managing hereditary breast cancer risk in women with and without ovarian cancer.
    Gynecol Oncol. 2017 Apr 25. pii: S0090-8258(17)30794.
    >> Share

  771. KATCHMAN BA, Chowell D, Wallstrom G, Vitonis AF, et al
    Autoantibody biomarkers for the detection of serous ovarian cancer.
    Gynecol Oncol. 2017 Apr 17. pii: S0090-8258(17)30775.
    >> Share

  772. PHILLIPS A, Balega J, Nevin J, Singh K, et al
    Reporting 'Denominator' data is essential for benchmarking and quality standards in ovarian cancer.
    Gynecol Oncol. 2017 Apr 12. pii: S0090-8258(17)30786.
    >> Share

  773. SHINN EH, Valentine A, Baum G, Carmack C, et al
    Comparison of four brief depression screening instruments in ovarian cancer patients: Diagnostic accuracy using traditional versus alternative cutpoints.
    Gynecol Oncol. 2017 Apr 8. pii: S0090-8258(17)30240.
    >> Share

  774. SIDDIQUI MK, Tyczynski J, Pahwa A, Fernandes AW, et al
    Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer.
    Gynecol Oncol. 2017 Apr 7. pii: S0090-8258(17)30770.
    >> Share

  775. SZENDER JB, Papanicolau-Sengos A, Eng KH, Miliotto AJ, et al
    NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30726.
    >> Share

  776. GARCIA-SOTO AE, Schreiber T, Strbo N, Ganjei-Azar P, et al
    Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30765.
    >> Share

  777. CREASMAN WT, Ali S, Mutch DG, Zaino RJ, et al
    Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30233.
    >> Share

  778. GRAYBILL WS, Pothuri B, Chase DM, Monk BJ, et al
    Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30724.
    >> Share

  779. SONG T, Kim MK, Jung YW, Yun BS, et al
    Minimally invasive compared with open surgery in patients with borderline ovarian tumors.
    Gynecol Oncol. 2017 Apr 2. pii: S0090-8258(17)30235.
    >> Share

  780. HERZOG TJ, Cohn DE
    Dose Dense Chemotherapy for Front-line Ovarian Cancer Treatment: The Price is Right?
    Gynecol Oncol. 2017;145:1-2.
    >> Share

    March 2017
  781. WARREN JL, Harlan LC, Trimble EL, Stevens J, et al
    Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study.
    Gynecol Oncol. 2017 Mar 31. pii: S0090-8258(17)30232.
    >> Share

  782. PARK JY, Kim DY, Suh DS, Kim JH, et al
    Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors.
    Gynecol Oncol. 2017 Mar 31. pii: S0090-8258(17)30239.
    >> Share

  783. BARBER EL, Dusetzina SB, Stitzenberg KB, Rossi EC, et al
    Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival.
    Gynecol Oncol. 2017 Mar 30. pii: S0090-8258(17)30230.
    >> Share

  784. SCOTT SA, van der Zanden C, Cai E, McGahan CE, et al
    Prognostic significance of peritoneal cytology in low-intermediate risk endometrial cancer.
    Gynecol Oncol. 2017 Mar 27. pii: S0090-8258(17)30228.
    >> Share

  785. BREGAR A, Deshpande A, Grange C, Zi T, et al
    Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
    Gynecol Oncol. 2017 Mar 24. pii: S0090-8258(17)30207.
    >> Share

  786. JANDIAL DA, Brady WE, Howell SB, Lankes HA, et al
    A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Mar 21. pii: S0090-8258(17)30229.
    >> Share

  787. K AU K, Peterson N, Truesdell P, Reid-Schachter G, et al
    CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
    Gynecol Oncol. 2017 Mar 16. pii: S0090-8258(17)30208.
    >> Share

  788. MCGEE J, Giannakeas V, Karlan B, Lubinski J, et al
    Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
    Gynecol Oncol. 2017 Mar 14. pii: S0090-8258(17)30153.
    >> Share

  789. JESKE YW, Ali S, Byron SA, Gao F, et al
    FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Mar 14. pii: S0090-8258(17)30152.
    >> Share

  790. NASIOUDIS D, Kanninen TT, Holcomb K, Sisti G, et al
    Prevalence of lymph node metastasis and prognostic significance of lymphadenectomy in apparent early-stage malignant ovarian sex cord-stromal tumors.
    Gynecol Oncol. 2017 Mar 11. pii: S0090-8258(17)30205.
    >> Share

  791. WYSHAM WZ, Schaffer EM, Coles T, Roque DR, et al
    Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
    Gynecol Oncol. 2017 Mar 10. pii: S0090-8258(17)30160.
    >> Share

  792. COWAN RA, Eriksson AG, Jaber SM, Zhou Q, et al
    A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2017 Mar 9. pii: S0090-8258(17)30121.
    >> Share

  793. DE ROOIJ BH, Ezendam NP, Nicolaije KA, Caroline Vos M, et al
    Effects of Survivorship Care Plans on patient reported outcomes in ovarian cancer during 2-year follow-up - The ROGY care trial.
    Gynecol Oncol. 2017 Mar 7. pii: S0090-8258(17)30162.
    >> Share

  794. VAN BROEKHOVEN ME, de Rooij BH, Pijnenborg JM, Vos MC, et al
    Illness perceptions and changes in lifestyle following a gynecological cancer diagnosis: A longitudinal analysis.
    Gynecol Oncol. 2017 Mar 6. pii: S0090-8258(17)30157.
    >> Share

  795. LEE M, Kim EJ, Cho Y, Kim S, et al
    Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer.
    Gynecol Oncol. 2017 Mar 5. pii: S0090-8258(17)30163.
    >> Share

    February 2017
  796. FOX E, McCuaig J, Demsky R, Shuman C, et al
    Corrigendum to "The sooner the better: Genetic testing following ovarian cancer diagnosis" [Gynecol. Oncol. 137 (2015) 423-429].
    Gynecol Oncol. 2017 Feb 27. pii: S0090-8258(17)30142.
    >> Share

  797. CHASE DM, Chaplin DJ, Monk BJ
    The development and use of vascular targeted therapy in ovarian cancer.
    Gynecol Oncol. 2017 Feb 23. pii: S0090-8258(17)30075.
    >> Share

  798. SAED GM, Diamond MP, Fletcher NM
    Updates of the role of oxidative stress in the pathogenesis of ovarian cancer.
    Gynecol Oncol. 2017 Feb 23. pii: S0090-8258(17)30154.
    >> Share

  799. KOMIYAMA S, Manrai M, Takahashi R, Takeya C, et al
    Safe dissection of high paraaortic lymph nodes superior to the renal vein in ovarian, primary peritoneal, or fallopian tube cancer by the "Komiyama's maneuver", a modification of Kocher's maneuver.
    Gynecol Oncol. 2017 Feb 22. pii: S0090-8258(17)30126.
    >> Share

  800. FELICES M, Chu S, Kodal B, Bendzick L, et al
    IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.
    Gynecol Oncol. 2017 Feb 21. pii: S0090-8258(17)30149.